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ABSTRACT 
The many benefits of regular physical activity (PA) have been well documented in the literature. 
PA has been shown to improve cardiovascular health and reduce the risk of cardiovascular 
disease. However, much less is known about the serious and sometimes fatal effects PA can have 
in individuals with certain rare cardiovascular diseases, such as arrhythmogenic right ventricular 
cardiomyopathy (ARVC). This cross sectional study sought to examine the association between 
PA and the onset and progression of ARVC caused by a p.S358L mutation in TMEM43. The 
sample consisted of 82 patients in who were diagnosed with ARVC caused by a p.S358L 
mutation in TMEM43 and had received an implantable cardioverter defibrillator (ICD) as 
primary prophylactic (PP) treatment. Survival analyses were done on several clinical cardiac 
symptoms, cardiac test abnormalities, and demographic variables from prior to ICD implant 
using the Kaplan-Meier product limit method to determine their association with time to 
appropriate firing of the ICD. Relative risk (RR) was calculated using the Cox regression model. 
Having an abnormal 24 hour Holter monitor test result prior to receiving the ICD and reporting 
high levels of moderate to vigorous PA were found to be associated with appropriate discharge 
of the ICD with RR’s of 4.1 (CI 1.2-13.7) and 12.8 (CI 3.7-45.2) respectively. A multivariate 
Cox regression model showed high levels of moderate to vigorous PA and having an abnormal 
24 hour Holter monitor result prior to ICD implant to be strongly associated with appropriate 
firing of the ICD with RR’s of 28.1 (CI 6.9-114.2) and 16.4 (CI 3.8-71.5). These results suggest 
that high levels of moderate to vigorous PA could play an important role in the phenotypic 
expression of ARVC caused by a p.S358L mutation in TMEM43. 
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CHAPTER ONE: INTRODUCTION 
1.1 Rationale 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic heart condition that can 
result in arrhythmias, heart failure and sudden cardiac death (SCD). It is most commonly 
characterized by fibrofatty replacement of the heart muscle quite often in both ventricles. 
Diagnosis of ARVC is often very difficult because many of the associated symptoms can be 
nondescript or even absent. ARVC is typically diagnosed using the Task Force Criteria (TFC) 
which uses a combination of known clinical test results and family history to create a diagnostic 
score [1]. The TFC has been modified in recent years to include the status of known disease 
causing mutations. Currently there are 12 known loci and eight identified genes for ARVC.  
While considered to be rare in the general population, with a prevalence of approximately 1 in 
5000 [2] there are some regions of the world where it has been found to be more common. In 
Newfoundland, Canada extensive research has shown a strong genetic link in several families. 
Linkage analysis showed that the disease was at locus 3p25 and subsequent molecular work 
determined the causative gene to be TMEM43, with the causative mutation a p.S358L missense 
[3]. This discovery now allows for early and accurate pre symptomatic diagnosis of the disease 
allowing for timely prophylactic treatment, and a decrease in overall morbidity and improved 
survival. Treatment for this disorder is the implantable cardioverter defibrillator (ICD) which 
monitors heart rhythm and provides an electric discharge if a malignant heart rhythm is detected , 
returning the heart to a normal sinus rhythm 
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Since the discovery of the gene responsible for causing ARVC in families from Newfoundland 
and the ascertainment of a large affected population, there has been increased interest in 
identifying other factors that may influence the penetrance and progression of the disease. One 
area of interest is the role that physical activity (PA) may play in disease progression. 
 
Significant research has indicated that PA may put individuals with various genetic 
cardiovascular diseases, including ARVC, at an increased risk for SCD [4]. In a study examining 
SCD in adolescents and young adults in Italy [5] it was found that ARVC was associated with 
the greatest risk of SCD in young athletes. Another large postmortem survey of athletes in the 
United States found ARVC to be responsible for three percent of SCD [6]. In a 2006 study 
Kirchhof and his colleagues created a functional phenotype of ARVC in a mouse model and 
found endurance training accelerated the development of ARVC [7]. 
 
Decades of research have highlighted the importance of PA for controlling cardiovascular 
disease and other chronic illnesses. As such, it seems contradictory to suggest that with this 
cardiovascular disease PA may cause more harm than good in affected individuals. 
 
The present study sought to examine the association between PA and the onset and progression 
of ARVC caused by p.S358L in TMEM43 in a population of patients from Newfoundland, 
Canada who had received an ICD as primary prophylactic treatment (PP) (treatment based on 
genetic results, not clinical cardiac results). Treatment was determined to be PP if the patient had 
no previously reported ventricular tachycardia (VT), no clinical diagnosis based on TFC but 
tested positive for the p.S358L mutation. 
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1.2 Aims and objectives 
The primary objectives of this study were: 
1. To retrospectively evaluate past PA practices in patients with ARVC due to p.S358L 
TMEM43 prior to receiving an ICD for PP treatment. 
2. To determine if an association exists between reported PA in patients with ARVC 
caused by a p.S358L mutation in TMEM43 and time to appropriate discharge of their 
ICD. 
 
The secondary objectives of this study were:  
1. To assess other clinical cardiac symptoms and cardiac test abnormalities at the time 
of ICD implantation and determine their association to time to penetrance of ARVC 
caused by a p.S358L mutation in TMEM43 as determined by time to appropriate 
discharge of the ICD. 
2. To assess other modifiable risk factors such as body mass index (BMI) score and 
smoking status at the time of ICD implantation and determine their association to 
time to penetrance of ARVC caused by a p.S358L mutation in TMEM43 as 
determined by time to appropriate discharge of the ICD. 
 
This study will also serve to determine appropriate PA guidelines for patients who have received 
an ICD as PP treatment for ARVC caused by a p.S358L mutation in TMEM43. This will 
hopefully assist physicians, genetic counsellors and other health care providers on how to 
appropriately educate current and future patients with this specific mutation on safe PA 
guidelines. 
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CHAPTER TWO: LITERATURE REVIEW 
In order to gain an adequate knowledge base for this study an extensive literature review was 
conducted. The search was broken down into three general areas. The first served to provide 
significant background information on ARVC. This included the cause, symptoms, diagnosis and 
treatment of the disease. This second served to acquire more knowledge about the genetic 
subtype used in this study. The third was performed to understand current theories and research 
examining the impact PA can have on the onset and progression of ARVC.  The databases 
Pubmed, CINAHL and MEDLINE (OVID) were searched regularly from inception of the study 
until April 2016. The search used the following terms along with synonyms and related words: 
“Arrhythmogenic Right Ventricular Cardiomyopathy”, “Arrhythmogenic Right Ventricular 
Dysplasia”, “ARVC”, “ARVD”, “Physical Activity” and “Exercise”. The search was not limited 
by study design, date or language of publication.  
2.1 Arrhythmogenic Right Ventricular Cardiomyopathy  
ARVC is a rare cardiovascular disease that can cause SCD in young men and women, 
particularly if it is left undiagnosed. It is characterized as the gradual fibrous and fatty 
replacement of the myocytes in the right ventricle (and frequently the left ventricle) of the heart 
which can eventually lead to fatal VTs and heart failure.  To date there have been twelve 
different loci identified for ARVC, eight of which have been mapped to a specific gene sequence 
(i.e. the causative gene and underlying mutation (s) is known). The current research focused on a 
genetic form of ARVC caused by a p.S358L mutation in TMEM43 prevalent in Newfoundland, 
Canada. 
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2.1.1 History 
Historical medical literature indicates that ARVC has likely been present throughout the ages, 
however, very little was known about the disease until half a century ago, in 1961, when the first 
known cases of the disease were documented and described  [8]. At that time a review was 
published describing several cases of strong right atrial contractions of the right ventricular 
pressure curve, referred to as auricularisation [9]. It was not until the late 1970’s that a team of 
French cardiologists, led by Guy Fontaine, became the first group to name and describe the 
disease. The group called the disease arrhythmogenic right ventricular dysplasia. The term 
dysplasia was used because it was believed that the disease was caused by abnormal 
development of the right ventricle. Their report described six patients who had experienced 
sustained VT originating from the right ventricle [2]. The team also noted that fibrous fatty tissue 
was present throughout the myocardium and the patients had not previously been diagnosed with 
overt heart disease. 
 
In 1982 Marcus and colleagues were credited as the first group to provide a clinical description 
of arrhythmogenic right ventricular dysplasia and noted that the disease had a tendency to run in 
families. This was revealed when the group described 24 cases of arrhythmogenic right 
ventricular dysplasia including two members of the same family [10]. 
 
As researchers became more knowledgeable about the disease the name was more revised, and 
became ARVC. This change in name reflected the understanding that the development of the 
disease was the result of progressive changes to the myocardium rather than abnormal 
development as previously thought [9]. 
6 
 
 
In the thirty years since the first clinical description of ARVC there has been significant research 
by several groups, all with the common goal to more fully understand and explain the diverse 
and complex aspects of this unique disease. 
2.1.2 Pathophysiology  
ARVC is often described as a disease of the desmosomes, the very important intercellular 
adhesion cells in the heart muscle. The desmosomes provide mechanical connections between 
myocytes which aid in the electrical conduction of the heart muscle. Most known forms of 
ARVC have been genetically mapped to mutations in specific desmosomal proteins however 
others, such as TMEM43 and the subject of this thesis, have been linked to other, non 
desmosomal, proteins found  in the heart muscle [3]. The mutant desmosomal proteins can 
become very sensitive to the mechanical stress of the heart, especially over time. Repeated stress 
can cause myocyte death and the gradual fibrofatty replacement of the myocardium in the 
ventricles [11]. The fibrofatty replacement can cause thickening of the wall of the ventricle and 
can interfere with proper electrical conduction of the heart. Improper electrical conduction can 
lead to life threatening ventricular arrhythmias (VA).   
 
Current research is interested in examining if modifiable risk factors are associated with causing 
more rapid fibofatty replacement of the myocardium, thus expediting the disease progression and 
if there are potential factors that could help slow the fibrofatty replacement and preserve the 
myocardium in people affected with ARVC.  
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2.1.3 Diagnosis 
ARVC is a gradual disease with changes to the heart muscle occurring slowly over time. It is 
often very difficult to diagnose in the general population because the symptoms can be subtle or 
non-existent. ARVC is often described as having four clinical phases. The first phase is referred 
to as the concealed phase. During this time no discernable symptoms are present even though the 
heart may be beginning to experience some structural changes. The second phase is the overt 
phase in which noticeable changes have started  to occur in the heart and mild symptoms such as 
light-headedness or palpitations may be present. The third phase is weakening of the right 
ventricle. During this phase the right ventricle has become compromised and the patient would 
be at a high risk of experiencing a potentially life threatening arrhythmia. The fourth and final 
phase is characterized by the weakening of the left ventricle. During this phase the function of 
both ventricles is compromised and could result in heart failure. Risk for SCD is present during 
all four phases. 
 
In 1994 an International Task Force created clinical diagnostic criteria for ARVC based on 
various known features of the disease[4], these guidelines separated symptoms into major and 
minor categories and are often referred to simply as the TFC. A positive diagnosis required the 
presence of a combination of 2 major criteria, 1 major and 2 minor criteria or 4 minor criteria. A 
serious shortcoming of the original TFC was that it was based predominately on the presentation 
of clinical symptoms. This inherently created an ascertainment bias, in that people with mild 
disease may never be diagnosed because they do not exhibit any symptoms or people with 
advanced disease may be undiagnosed if their first clinical symptom is SCD.  Unfortunately 
ARVC, like most genetic diseases, can have variable expressivity or reduced penetrance which 
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can create difficultly in both diagnosing and determining how to treat the disease in different 
individuals. Variable expressively means that the disease can affect or be expressed differently in 
related individuals.  Reduced penetrance means that even though an individual may have the 
gene mutation the disease may never fully manifest.  
 
Overtime with technological advancements and increased knowledge of the disease several 
recommendations have been made to modify the original diagnostic criteria [1] and take into 
account genetic and other factors. The family history criteria were considerably revised and three 
new major criteria were created, these included; 1. ARVC confirmed in a first degree relative 
who met TFC 2. ARVC confirmed pathologically at autopsy or surgery in a first degree relative 
and 3. Identification of a pathogenic mutation categorized as associated or probably associated 
with ARVC. A table comparing the original and the revised TFC can be found in Appendix A. 
2.1.4 Treatment 
Currently there is no cure for ARVC; however several treatment options are available to patients 
that aim to control symptoms and prevent progression and potentially fatal arrhythmias 
associated with ARVC. With this being the case one of the most important factors in treating 
ARVC is early diagnosis.   
 
In patients determined to be at a lower risk for ARVC antiarrhythmic drugs, such as sotalol and 
amiodarone (in combination with β-blockers) are often prescribed to help control the occurrence 
of VT. In high risk cases ICDs  have become the preferred and recommended treatment method. 
The current recommendations are that unless clinical signs are present, then the ICD should not 
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be used for primary prevention [12]. For the genetic subtype highlighted in this study, primary 
prevention is the only method to stop early death [13] 
 
Identifying and avoiding known risk factors can also play a very important in role in controlling 
the symptoms and progression of this disease. One of the primary objectives of the current study 
was to investigate PA as a potential risk factor in the genetic subgoup of ARVC caused by a 
p.S358L mutation in TMEM43. 
2.1.5 ARVC caused by a p.S358L mutation in TMEM43 in Newfoundland and Labrador  
The province of Newfoundland and Labrador (NL) is considered to be genetically isolated 
making it an excellent location to study rare genetic diseases[14]. One genetic disease that is 
highly prevalent in NL is ARVC.   
 
In the late 1980’s a family in Newfoundland, Canada was identified to have an autosomal 
dominant (AD) form of ARVC. This type of ARVC was found to be linked to the short arm of 
chromosome 3 at 3p25 [15]. Over the next several years many additional families were found to 
be linked to the same chromosomal area and could be identified by a set of DNA markers 
referred to as a haplotype. Extensive research began on this population, collecting data both 
retrospectively and prospectively, reviewing medical records and family histories, spanning over 
several generations. Data was collected on the patients with confirmed ARVC as well as their 
first degree relatives. Using the previously established ARVC TFC, new guidelines appropriate 
to this population were established to identify both low and high risk patients in this population. 
Originally, a patient was considered to be at a high risk of having ARVC if they had documented 
sustained VT or SCD before the age of 50, the presence of the known high risk DNA haplotype 
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after genetic testing, or they had been determined to be an obligate carrier (having a parent and 
offspring affected with ARVC). 
 
In 1998 a cardiomyopathy genetics research clinic was established in St. John's Newfoundland at 
the Health Sciences Centre. At that time all patients born at an a priori 50% risk of ARVC (either 
affected themselves or had a first degree family member affected) were able to receive the 
genetic haplotype testing. ICDs were offered to all patients found to possess the high risk DNA 
haplotype and had an abnormal clinical test consistent with the ARVC TFC. In this population 
ICD therapy was shown prior to the causative gene being discovered to significantly decrease 
mortality in patients receiving the ICD for secondary or primary therapy for ARVC [15], a 
situation which has recently been confirmed with 10 years further follow up [16]. 
 
Over the next ten years a large cohort of 496 affected patients and their first degree relatives 
from fifteen different families were identified. This established population provided invaluable 
information about the disease. In 2008, using positional mapping, researchers were able to 
identify the gene TMEM43 [3], and determined it to be caused by a p.S358L missense mutation. 
At that time all previously identified clinically affected patients were found to be mutation 
carriers. It was also concluded that males had disease associated symptoms, heart failure and 
death at a much younger age when compared to affected females [3]. With the gene discovery 
diagnosis could now be made directly following direct mutation analysis, allowing for diagnosis 
to be made before the onset of clinical symptoms and without requiring the presence of any 
abnormal clinical test results. This is of particular importance with this type of ARVC because 
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expression of the disease is highly variable and many affected individuals often do not fulfill 
TFC for diagnosis [16]. 
 
The extensive, multigenerational data collected from this cohort has been used to gain a better 
understanding of this disease and continue to improve diagnostic criteria to allow for earlier 
detection and appropriate treatment. In this population ICD therapy has shown significantly 
improve survival in both males and females [13, 15]. Because males were shown to develop 
symptoms at a younger age, all post-pubertal males who tested positive for the gene mutation 
were offered ICD therapy. Females who tested positive for the gene mutation were typically 
offered ICD therapy after they received an abnormal result on a clinical cardiac test [13]. An 
ICD was considered to be secondary prevention therapy if it was given following a clinically 
documented episode of sustained VT/VF. If no previous VT/VF had been reported before the 
ICD was implanted, treatment was considered to be primary prevention.  The ICDs in this 
population were programmed to discharge (fire) when a patient experienced a sustained VT/VF 
or VT/VF of greater than 240 beats per minute (bpm). These limits indicate serious cardiac 
events and thus the time of a first appropriate discharge of the ICD is considered an event that 
would have been synonymous with death, had the ICD not been present. Analysis of ICD data in 
this population supports this theory [13]. 
 
Because of the high mortality associated with this genetic subtype of ARVC the genetic mutation 
testing and use of ICDs for treatment have been able to significantly improve disease associated 
mortality in this population. However, because the variable expression of the disease is wide it is 
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important for researchers to examine other risk factors that may contribute to penetrance and 
expression of this disease, such as PA. 
2.2 Physical Activity and the Heart 
PA is defined as any bodily movement produced by the skeletal muscles that requires energy 
expenditure [17]. PA can include exercise as well as non-exercise activities. Exercise is 
considered to be a planned activity that is structured and repetitive in nature with the intention to 
maintain or improve an individual’s health [18].  
2.2.1 Measurements of Physical Activity 
PA is often considered a modifiable risk factor for many diseases. As such, the measurement of 
PA is essential in epidemiological research to determine its association with a variety of health 
outcomes [19]. Numerous methods are available to measure PA both objectively and 
subjectively. The most practical and widely used method is the use of interviewer or self-
administered questionnaires [20, 21]. Questionnaires often ask participants to recall PA habits 
over a defined period of time (past 24 hours, past week, past year and even lifetime). They are 
often inexpensive, easy to use for large groups and are minimally invasive to participants [21-
24].  
 
One of the most commonly used questionnaires, particularly in cardiovascular research, is the 
Paffenbarger Physical Activity Questionnaire (PPAQ), also referred to as the Harvard Alumni 
Activity Survey and the College Alumni Questionnaire [25] 
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There are objective measures to assess PA. The two most common methods are the use of 
accelerometers and direct cardiorespiratory testing. Accelerometers are devices, which are worn 
by participants to measure frequency, intensity and duration of PA for a specific period of time 
[26]. Cardiorespiratory testing is typically done in a laboratory setting, using a treadmill or cycle 
ergometer to measure maximal (or submaximal) oxygen uptake (VO2max). Both measurements 
have been shown to provide accurate estimates of PA; however they are often costly and can be 
very onerous to participants. Both of these methods are often used to assess the validity of PA 
questionnaires [27].  
 
In research PA is often measured by the type of activity and its intensity. In 1993 the 
Compendium of Physical Activities (CPA) was created as a resource to promote consistency in 
PA measurement across research [28], it was updated in 2000 and again in 2011 [29, 30]. The 
CPA is an extensive list of common physical activities with corresponding intensity values. The 
intensities are measured using a value referred to as a metabolic equivalent or MET. The MET 
values were created based on pre-determined energy costs for certain activities [31]. A MET 
value of one is considered to be the amount of oxygen that is metabolized at rest while seated 
and is equivalent to 3.5 mL/kg/min of oxygen consumption [32].  
2.2.2 Cardiovascular Benefits of Physical Activity 
Decades of research have shown the irrefutable benefits of PA for cardiovascular and overall 
health. The American Heart Association (AHA) lists sedentary lifestyle as one of five major risk 
factors for cardiovascular disease, along with high blood pressure, abnormal blood lipids 
profiles, smoking and obesity[33]. Extensive research has shown that decreasing any of these 
risk factors could greatly reduce an individual’s chance of having a heart attack or experiencing 
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another cardiac event. Regular exercise and PA can play an important role in reducing several of 
these known risk factors [33-36].  
2.2.3 Physical Activity Guidelines for Cardiovascular Health  
With the many known benefits of PA for promoting health and preventing disease, guidelines 
were created to provide the public with healthy and safe PA recommendations needed to gain 
optimal health benefits. In 1996 the Surgeon General released a report with the intention to 
promote PA in the United States [37]. This report was supported by the Centers for Disease 
Control and Prevention (CDC), the American College of Sports Medicine (ACSM) and The 
National Institutes of Health (NIH) [38, 39]. Similar guidelines were also adopted in Canada by 
the Canadian Society of Exercise Physiology (CSEP) [40] and internationally by the World 
Health Organization (WHO) [17]. 
 
Current Canadian guidelines recommend, adults aged 18 to 64 years, should accumulate at least 
150 minutes per week of moderate to vigorous intensity PA to achieve health benefits[40], with 
more PA providing greater benefits.  American health organizations provide similar 
recommendations but also emphasize that for additional and more extensive health benefits, 
adults should increase their moderate to vigorous PA to 300 minutes per week[38]. 
 
These guidelines for minimal PA required for optimal cardiovascular benefits are well 
established, actively promoted and made readily available to the general public. Unfortunately, 
there are few resources available in terms of guidelines for whether or not an upper limit exists 
of how much PA is too much and may actually cause an individual more harm than good. With 
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more recent guidelines recommending even higher levels of weekly PA there may be a need to 
establish additional recommendations on how much is too much. 
 2.2.4 Adverse Cardiovascular Adaptations to Physical Activity  
Individuals who are very physically active are often perceived to be healthy and can appear to be 
impervious to illness because of their superior level of physical fitness. Over the past several 
decades significant research has looked at the impact that high level PA can have on the 
cardiovascular system. It is well established that high levels of regular PA can cause structural 
and functional changes to the heart [5, 41, 42] often referred to as “athlete’s heart”. Changes can 
include increased cardiac mass and dilation of the both the atria and ventricles. These changes 
are typically not harmful and are considered a natural adaptation to training; however, there is 
significant evidence to suggest, that in some cases, these adaptations can become harmful and 
even fatal. 
 
In 2006 a study was conducted using both biochemical and electrocardiographic assessments to 
examine myocardial injury after endurance exercise [43]. Twenty seven participants were 
evaluated one week before completing an ultra-endurance triathlon, as well as immediately after 
and one week later. Cardiac troponin I (cTnI) and B-type natriuretic peptide (BNP), known 
markers of myocyte damage were measured and right ventricular function was assessed. At 
baseline right ventricular function was normal in all athletes, post raced measurements showed 
significant right ventricular dysfunction. Both cTnI and BNP were significantly increased after 
exercise in 57.7% and 100% of participants respectably, indicating that myocardial injury had 
occurred. All levels returned to normal one week after the race. 
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This study hypothesized that the right ventricle, when compared to the left, is less capable of 
accommodating the sustained increased cardiac output experience during endurance exercise, 
and that the abnormal loading of right ventricular myocytes can result in damage and 
dysfunction. An increase in pulmonary artery systolic pressure (PASP) during exercise can also 
increase the afterload demands of the right ventricle causing damage. This study showed acute 
damage to the right ventricle following endurance exercise but speculated that repeated damage 
could lead to more serious chronic dysfunction such as VAs and even SCD.  
 
Another study evaluated 46 high level endurance athletes who had participated in sports for more 
than two hours a day, three times a week for more than five years. All participants were being 
evaluated for symptoms associated with VA [44]. Using the original TFC for ARVC it was 
found that the right ventricle was implicated in 86% of the ventricular arrhythmias. After being 
followed up for a median of 4.7 years 18 of the 46 athletes (39%) had developed a major 
arrhythmic event, including nine who experienced SCD. This study was important because it 
showed that elite athletes presenting with arrhythmias often have a high level of irreversible right 
ventricular damage which can eventually result in severe arrhythmias and SCD. This indicates 
that endurance sports could play a major role in the development or progression of right VA and 
dysfunction.  
 
There is often much attention when a young, athlete dies suddenly. The visibility of these cases 
in the media has led to an increased interest in research investigating the potential causes of 
death in these seemingly healthy individuals. For instance, in 2007, it was highly publicized 
when rising elite Spanish soccer player, 22 year old Antonio Puerta suddenly collapsed on the 
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field in the middle of a match. He was taken to hospital and later died. The autopsy indicated that 
complications from undiagnosed ARVC were responsible for his death [45]. Closer to home, in 
2013, a 16 year old Quebec Major Junior Hockey League prospect from Nova Scotia died on the 
ice during training camp [46]. It was later revealed that he too had undiagnosed ARVC [47].   
 
While there are many potential causes of SCD in young athletes, ARVC has frequently been 
implicated as one of the major causes.  
2.3 Physical Activity and Arrhythmogenic Right Ventricular Cardiomyopathy 
In the early 1990’s Corrado et al. [48] investigated the cause of SCD in 22 young competitive 
athletes from the Veneto region of Italy. They found that in 18 of the 22 cases death had 
occurred during or immediately following PA. The 6 patients (all male), diagnosed with ARVC 
all died during exercise. 
 
In a subsequent study Corrado et al [5] sought to evaluate the risk of SCD in adolescents and 
young adults participating in competitive sports also in the Veneto region of Italy. They reported 
that PA was associated with a 2.5 times increased risk of SCD. They also reported that in SCD 
cases in patients with ARVC, athletes were significantly younger than non-athletes. It should be 
noted that the Veneto region of Italy is well known to have a high incidence of ARVC 
attributable to a genetic factor in that area [12, 49-52]. In 1994 Rampazzo and colleagues found 
the ARVC in that region was caused by a mutation in the TGFβ3 gene at 14q23-q24 and the 
incidence could be as high as 4.4/1000 [51].  
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Another Italian study evaluated 32 athletes, 28 males and 4 female, with a mean age of 23 and 
followed them for 6.7 years [53]. All athletes were previously asymptomatic but had been 
referred to the study centre for suspected or documented arrhythmias. The study took place 
before the original TFC for ARVC were established so diagnosis was based on a series of 
echocardiographic and angiographic test as well as clinical symptoms. Using these criteria all 
athletes were diagnosed with ARVC. During follow up severe symptoms developed in 50% of 
the athletes, 81% of the symptoms occurred either during or immediately following participation 
in sports, including two cases of SCD. This study concluded that ARVC was present in the 
athletic population, often with no clinical symptoms and it did not affect athletic performance. 
Unfortunately, it showed that athletes with ARVC are at a high risk of developing severe 
arrhythmic symptoms often during or following physical exertion. It was believed that PA could 
play a role in activating several arrhythmogenic mechanisms. 
 
A study in the United Kingdom sought to examine the etiology of SCD in athletes [54]. They 
included 118 athletes in their study between 1996 and 2008. The athletes in this study were 
predominately amateur and recreational athletes.  Researchers found that most deaths had 
occurred during or immediately following exercise. Cardiomyopathies were found to be the most 
common cause of death responsible for 62% of the cases. ARVC specifically, was attributable to 
14% of the deaths. 
 
More research was needed to further examine why PA was so strongly associated with the 
presentation of clinical symptoms and cardiac events in people with ARVC. It was well 
established that ARVC was a disease that can be caused by mutations in proteins responsible for 
19 
 
cellular adhesion of the cardiac myocytes known as desmosomes [11, 55-59].  Some of these 
proteins include plakophilin, plakoglobin, desmoglein and plakoglobin. It is believed that 
mutations in these proteins will lead to impaired adhesion and conductivity between the 
myocytes eventually leading to dysfunction of the right ventricle and fibrofatty replacement of 
the damaged myocytes. To further support the role of desmosomal damage as a cause of ARVC 
a mouse model was created [7]. Investigators also wanted to examine if mechanical stress, 
caused by PA could alter the phenotypic expression of ARVC. The investigators found by using 
heterozygous plakoglobin deficient mice they were able to create a functional phenotype of 
ARVC. Over ten months the plakoglobin deficient mice had both increased right ventricular 
volume and reduced right ventricular function and that left ventricular size and function had not 
been affected.  
 
To test the effect of mechanical stress from PA the mice were put on a daily swimming program 
with the duration increasing from 5 to 90 minutes per day over eight weeks. The endurance 
training caused premature right ventricular dilation and dysfunction at 5 to 6 months of age. 
There was no difference in left ventricular size or function after the training program. This study 
showed that in an ARVC mouse model, right ventricular dysfunction and arrhythmias can be 
accelerated by endurance training. This indicates that mechanical stress, caused my physical 
exertion could impact phenotypic expression of ARVC.  
 
The previous studied showed that ARVC can have variable phenotypic expression in a mouse 
model and that it can be influenced by environmental or modifiable risk factors, such as PA. A 
study by James et al. sought to investigate if exercise can influence penetrance of ARVC in 
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patients with desmosomal mutations [60]. The study included 87 participants, 46 male and 41 
female with various desmosonal mutations. Their results showed that participants who were 
described as endurance athletes had a different presentation and clinical course when compared 
to their nonathlete counterparts. Athletes were found to have more clinical symptoms and 
develop symptoms at a younger age more often than nonathletes. This study showed for the first 
time in humans that the amount and intensity of exercise can increase the likelihood of 
developing VA and heart failure in people with ARVC with known desmosomal mutations. 
 
Another study by Saberniak et al. [61] examined the impact that high level PA can have on 
myocardial function in patients with ARVC. As we saw before, during PA cardiac output is 
increased causing increased stress on the walls if the ventricles from volume overload [43, 62], 
this study used echocardiography and MRI to assess myocardial function in athletes and non-
athletes. The revised TFC [1] were used to determine diagnosis of ARVC. Participants were 
considered to be an athlete if they reported participating in vigorous PA (activities with a MET 
value > 6) for greater than 260 minutes per week for a minimum of 4 years. In total 110 
participants were included in the study, 37 of whom were determined to be athletes. The results 
showed that athletes had reduced right ventricle and left ventricle function when compared to 
non-athletes. Athletes were also diagnosed with ARVC and had onset of VA at a younger age 
than non-athletes. This study indicates that exercise could aggravate and accelerate myocardial 
dysfunction in patients diagnosed with ARVC. 
 
All the previously presented research has shown a strong association between PA and the onset 
and progression of ARVC. These studies have implicated mechanical stress on the right ventricle 
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and subsequent myocyte damage and dysfunction from increased cardiac output during PA as the 
primary culprit in the accelerated fibrofatty replacement of the right ventricles. However another 
pathway may also be involved accelerating the damage to the right ventricle and it may be of 
particular importance in ARVC caused by the p.S358L mutation in TMEM43. 
 
Several studies have shown a reduction in the canonical Wnt/β-catenin signaling pathway in 
ARVC [55, 63, 64]. It is believed that plakoglobin can become separated from its desomosomal 
complex and then competes with β-catenin consequently suppressing the pathway. When the 
canonical Wnt/β-catenin pathway is suppressed the signaling pathway of the adipogenic 
transcription factor peroxisome proliferator activated receptor gamma (PPARγ) is activated. An 
activated PPARγ is able to activate a target gene when it binds to a peroxisome proliferator 
response element (PPRE) found on the gene.  
 
Because of the vast clinical importance of PPAR’s, particularly their ability to regulate genes 
through PPRE’s a scan was done of the entire genome to identify target genes of PPAR [65]. 
One of the many target genes with a PPRE was TMEM43, the gene containing the p.S358L 
mutation in the families used in this study. This could indicate that if TMEM43 is part of the 
PPAR pathway, dysregulation could contribute to the fibrofatty replacement of the right ventricle 
and the mechanical stress created by PA may increase the amount of plakoglobin being separated 
from the desomosomes which in turn could upregulate PPARγ signaling and promote fibrofatty 
replacement to an even greater extent. 
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Additionally it is well established that PA is associated with the generation of PPARγ ligands 
which are needed to activate PPARγ signaling events [66-70]. The increased presence of these 
ligands in individuals with ARVC could be associated with the increased phenotypic expression 
of the disease in people who are more physically active.  
2.4 Summary  
Based on the current literature it is well established that in individuals diagnosed with ARVC, 
normal levels of myocardial stress can lead to damage and dysfunction of the right ventricle 
resulting in fibrofatty replacement of the myocardium.  Research also indicates that in 
individuals with healthy hearts, excessive levels of myocardial stress, caused by high levels of 
PA, can lead to damage and dysfunction of the right ventricle, resulting in transient myocardial 
damage and fibrofatty replacement of the myocardium. As such it is hypothesized that in 
individuals diagnosed with ARVC, excessive levels of myocardial stress, caused by high levels 
of PA can lead to accelerated myocardial damage and dysfunction and subsequent fibrofatty 
replacement of the right ventricle. Figure 1 summarizes the hypothetical potential pathways to 
explain how PA may contribute to accelerated phenotypic expression of ARVC in affected 
individuals.  
 
Currently there is a gap in the existing knowledge as to the various factors contributing to ARVC 
progression, specifically the role of physical activity on disease progression and expression.  
 
The current study sought to evaluate PA levels in an established cohort of patients diagnosed 
with the genetic subtype of ARVC caused by the p.S358L mutation in TMEM43 in 
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Newfoundland, Canada to determine if an association exists between high levels of PA and 
expression of disease. 
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Figure 1: Hypothesized effects of physical activity in ARVC
1
 
   
                                                 
1
 Figure was created by the author to summarize the hypothesized effects of physical activity in ARVC from the 
literature. 
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CHAPTER THREE: METHODS 
3.1 Ethical Considerations  
Ethics approval was obtained from the Human Research Ethics Board of the Faculty of 
Medicine, Memorial University of Newfoundland (Appendix B) and the Research Proposals 
Approval Committee (RPAC) of Eastern Health (Appendix C), HIC # 08.157. 
 
Patients living in Newfoundland were first introduced to the study by their cardiologist when 
they attended an ICD clinic at the Health Science Center in St. John's, Newfoundland. The 
cardiologist explained the rationale, purpose, possible risks and benefits, as well as the 
requirements to participate in the study. Patients were then given the opportunity to review the 
consent form and ask questions before choosing to accept or decline participation in the study. If 
the patient agreed to take part in the study they had the option to meet with the primary 
investigator (PI) and complete the questionnaire at that time or take the questionnaire to 
complete at home and return later. Patients who were not scheduled to attend the ICD clinic for 
several months were informed of the study over the phone by the cardiologist. If they agreed to 
participate in the study consent forms and additional study information were sent to them the 
mail. Those patients were contacted by phone to complete the questionnaire after their signed 
consent forms were returned to the PI. 
 
Patients living outside of Newfoundland and the next of kin (NOK) of deceased patients were 
introduced to the study over the phone by a genetics counsellor well known to the patients. The 
genetics counsellor explained the rationale, purpose, possible risks and benefits, as well as the 
requirements to participate in the study. If the patient or NOK agreed to take part in the study 
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consent forms and additional study information were sent to them the mail. Those patients and 
NOK were contacted by phone to complete the questionnaire after their signed consent forms 
were returned to the PI. 
 
All patients and NOK were advised of the precautions that would be taken to ensure anonymity 
and confidentiality of all information. This included storing all collected information in a locked 
office that only investigators would have access to. All paper files were stored in the office in a 
locked filing cabinet and all electronic information was stored on a password protected computer 
with all personal identifiers removed. 
3.2 Study Participants 
An extensive dataset containing 496 patients (270 males, 226 females) had previously been 
established from a large study investigating the genetic epidemiology of ARVC in NL [3] and 
found to be part of a family that was segregating the TMEM43 p. S358L mutation. The cohort 
used for this study included fifteen families in NL. Data for the original cohort study was 
collected both retrospectively and prospectively using all available medical records. In total 1009 
variables were collected on each patient and all data was stored in the original database. To be 
included in the study patients had to be born at an a priori 50% risk of inheriting ARVC caused 
by a p.S358L mutation in TMEM43. This therefore included all those now shown to be affected, 
all those now shown to be unaffected (who were born at 50% risk), obligate carriers and those 
remaining at a 50% risk because they have not yet been tested. 
 
The current study was interested in investigating the association of clinical symptoms, cardiac 
test abnormalities and other demographic variables, specifically PA, at the time of ICD implant 
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and the progression and expression of their disease. As such the investigators were required to 
identify an accurate measurement to assess disease progression. Previous research on the original 
cohort had shown ICD therapy to significantly improve survival in affected patients, particularly 
males [13, 15]. This research has recently been added to and strengthened [13].  
 
Recommendations were made at the time of the first paper [15] for ICD therapy to be used as 
both primary and secondary treatment in patients with a high genetic risk of ARVC caused by a 
p.S358L mutation in TMEM43.  Typically ICD’s are programmed to discharge or “fire” when a 
potentially lethal arrhythmia occurs in the heart [71]. The rate at which the device fires is 
determined by the cardiologist who is sets up the device. Most devices will appropriately 
discharge when they detect any period of sustained VT. The previous papers on this cohort chose 
sustained VT at any rate or a rate >240 bpm to be an appropriate firing of the device [13, 15]. 
The rate of >240 bpm was chosen to reflect the worst events because at that rate the event would 
have been fatal, so a discharge at a heart rate (HR) of >240 bpm is considered an aborted death 
[15]. 
 
For the purpose of the current study, appropriate discharge of an ICD for sustained VT at any 
rate or VT >240 bpm was used as the measurement to determine advanced disease progression or 
phenotypic expression. The first criterion therefore, for study eligibility, patients had to have 
received an ICD as therapy for their disease. To ensure patients had a similar risk profile and did 
not already have advanced disease only patients who had received an ICD as PP therapy were 
included. The treatment was previously determined to be a PP therapy if the patient had no 
documented history of VT prior to implantation of the device. This information had been 
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recorded and was retrieved from the original database from the large cohort study. From the 
original 496 patients, 110 had received ICD’s. Of the 110 patients with ICD’s 82 had received 
the ICD as a PP therapy and were included in the current study (Figure 2). 
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Figure 2: Flow diagram of patients included in study. 
 
 
3.3 Data Collection 
Data collection took place from February 2009 to July 2010 and all new variables were added to 
the original dataset. All eligible patients (or NOK) were asked to completed a modified version 
of the PPAQ (Appendix D) [72], to assess the patients past PA habits in the year prior to 
receiving their ICD. 
30 
 
3.3.1 In-person and phone interviews 
Data was collected from three groups of patients. One group included patients who were 
currently living and receiving treatment in Newfoundland. The second group included patients 
living and receiving treatment outside of Newfoundland and the third group included deceased 
patients.  
 
All patients in the first group were in regular contact with a cardiologist and attended an ICD 
clinic at the Health Science Center in St. John's, Newfoundland every 6 to 12 months. These 
patients were introduced to the study by their cardiologist when they attended the clinic for their 
regularly scheduled appointments. The study was explained to the patients by their cardiologist 
and they were given the opportunity to ask any questions. If they were interested in participating 
they were directed to meet with the PI at that time. The PI further explained the study, answered 
questions and obtained consent. Patients were then asked to complete a short questionnaire with 
the assistance of the PI. Patients were also given the option to take the questionnaire home and 
return it to the PI once completed, however all patients choose to complete the questionnaire at 
that time.  
 
Information was collected from 56 patients who had attended the ICD clinic. Two patients had 
received heart transplants and were no longer required to attend the clinic. These patients were 
contacted and introduced to the study over the phone by the cardiologist. Both patients agreed to 
participate in the study and were sent consent forms in the mail. Once the consent forms were 
returned to the investigator, the PI contacted the patients by phone and administered the 
questionnaire. 
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Several patients were living in rural areas of the province and have their ICD's monitored by a 
specialist in central Newfoundland. These patients only attended the ICD clinic at the Health 
Science Center in St. John’s every twelve months. To ensure that the data was collected in a 
timely manner ten of these patients were contacted and introduced to the study over the phone by 
the cardiologist. If they agreed to participate they were sent consent forms in the mail. Once 
consent forms were returned to the PI the patients were contacted by phone and the questionnaire 
was administered.  
 
The second group of patients were living and receiving treatment outside of Newfoundland. All 
of these patients were in regular contact with a genetics counselor in Newfoundland. The 
genetics counselor contacted each of these patients and informed them of the current study. If the 
patients agreed to participate they were sent a package from the PI. The package included: an 
instructions sheet clearly explaining what needed to be signed and returned to investigators ; 
several “Release of Information” forms to allow researchers to receive any new information from 
clinics or hospitals attended by the patient that may be important for the study;  two consent 
forms, one to be signed and witnessed and returned to investigators and the other to be kept for 
the patients personal records; and an addressed and prepaid envelope to return all information to 
the investigators. Once consent forms were returned and received the PI contacted the patients by 
phone and administered the questionnaire over the phone. Of the fourteen patients identified as 
living outside of Newfoundland thirteen were successfully contacted and participated in the 
study.  
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The final group included two patients who had received ICD's as PP treatment for ARVC caused 
by a p.S358L mutation in TMEM43 but were deceased at the time of the study. NOK, who had 
previously been in contact with the genetics counselor, were identified and the genetics 
counselor made several attempts to contact these patients. One NOK was successfully contacted 
and agreed to take part in the study. Two consent forms were mailed to the NOK one to be 
signed and witnessed and returned to investigators and the other to be kept for their personal 
records. Once consent forms were returned and received the PI contacted the NOK by phone and 
administered the questionnaire over the phone. The NOK for the remaining patient was unable to 
be contacted and was therefore not included in this study. 
 
All patients and NOK gave the investigators permission to use any previously collected 
information that would be useful for the current study. This included reviewing the patient files if 
necessary and utilizing any information from the preexisting dataset. 
3.4 Physical Activity Assessment  
3.4.1 Modified Paffenbarger Physical Activity Questionnaire 
For this study a modified version of the PPAQ (Appendix D) was chosen to retrospectively 
access the PA levels of the patients from the year before they received their ICD. This 
questionnaire was selected because it was valid and reliable and allowed patients to easily report 
previous PA habits. It was also considered to be a good questionnaire for accurately reporting 
moderate and vigorous PA [22]. 
 
For this questionnaire patients were first asked to report how many flights of stairs (1 flight= 10 
stairs) and how many kilometers they typically walked each day.  Next, they were asked to list 
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any sports, leisure and recreational activities they participated in during a typical week, as well 
as how many times per week and the amount of time spent doing the activities. The next section 
asked them to report seasonal activities that were only done at certain times throughout the year. 
They were asked to report how many weeks per year they did the activity and for how long they 
participated in it. The final question asked patients to report how many times per week they 
participated in an activity that caused their HR to increase or cause them to become short of 
breath.  
3.4.2 Calculation of Physical Activity  
Total PA was calculated by how many minutes per week patients reported being physically 
active.  Each reported activity was assigned a MET value from the CPA [30]. Activities with a 
MET value of less than 3 were categorized as light PA. Activities with MET values between 3 
and 5.9 were categorized as moderate PA. And finally all activities listed with a MET value of 6 
or greater were categorized as vigorous activity. For each patient, the total minutes per week 
spent in each category of PA (light, moderate and vigorous) was calculated. For analysis three 
categories were created using the current PA guidelines and recommendations created by the 
American College of Sport Medicine [73], the Canadian  Society of Exercise Physiology [40] 
and the World Health Organization[17]. These categories included: 1. Patients who were not 
meeting the current guidelines (reporting <150 minutes/week of moderate to vigorous PA), 2. 
Patients who were meeting the current guidelines (150-299 minutes/week of moderate to 
vigorous PA) and 3. Patients who were exceeding the current guidelines (>300 minutes/week of 
moderate to vigorous PA). 
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3.5 Data Analysis 
All new collected variables were added to the preexisting database in SPSS version 16. Analysis 
was completed using IBM SPSS Statistics version 19. 
 
A cross-sectional analysis was performed to examine the association between self-reported PA 
and the expression of ARVC caused by a p.S358L mutation in TMEM43. The outcome variable 
of interested was defined as the presence or absence of the ICD appropriately firing. The primary 
exposure variable of interest was self-reported weekly minutes of participating in moderate to 
vigorous PA. 
 
Survival analyses were performed to determine if associations existed between several possible 
covariates and the time to appropriate firing of the ICD using the Kaplan Meier product limit 
method and Cox regression analysis to determine relative risk (RR). A p-value of <0.05 was 
considered significant.  
 
The analysis was performed for the presence or absence of cardiac symptoms prior to receiving 
the ICD as well as the age in which the ICD was implanted. The cardiac symptoms assessed 
included heart palpitations (a noticeable rapid or irregular heartbeat), pre-syncope (feeling of 
lightheadedness with loss of consciousness), chest pain and syncope (temporary loss of 
consciousness). Age in which the ICD was implanted was categorized into four groups; received 
the ICD before or equal to 30 years of age, 31-40 years of age, 41-50 years of age and greater 
than or equal to 51 years of age.   
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The results from four clinical cardiac tests prior to ICD implant were also examined. These tests 
included a 12 lead electrocardiogram (ECG), a signal average electrocardiogram (SAECG), a 24 
hour Holter monitor test and an echocardiogram. These clinical tests were included because the 
presence of an abnormal result of one of these tests prior to ICD implantation could indicate a 
more advanced disease stage and be predictive of appropriate discharge of the ICD. The ECG 
was considered abnormal if it showed poor R wave progression. The SAECG test was deemed 
abnormal if the patient exhibited abnormal results on 2 of 3 previously recognized criteria [74].  
The Holter monitor test is used to monitor the heart rhythm continuously for a period of time, in 
this case is was used for 24 hours. The presence of  >200 premature ventricular contractions 
(PVC) on the 24 hour Holter monitor test was considered to be abnormal.  The echocardiogram 
was considered abnormal if the patient exhibited left ventricular enlargement with left ventricular 
end diastolic diameter  >112% at 2 standard deviations above the predicted mean according to 
Henry’s formula [75].  
 
Three demographic variables were evaluated, sex, BMI category (normal, overweight or obese) 
and smoking status (ever or never). BMI is a calculation in which a person’s weight in kilograms 
is divided by their height in meters squared. A BMI calculation of 18.5-24.9 is categorized as 
normal, a BMI of 25-29.9 is categorized as overweight, and a BMI of 30 or greater is considered 
obese. 
 
Finally three variables accessing PA levels were used. These included reporting weekly vigorous 
activity (yes or no), reporting having an increased HR from PA (>3 times per week or < 3 times 
36 
 
per week) and reported weekly minutes of moderate to vigorous PA (<150 minutes per week, 
150-299 minutes per week or >300 minutes per week).  
 
Because of the well-known differences in the expression of ARVC caused by the p.S358L 
mutation in TMEM43 in males and females [3] sex was included in the final multivariate Cox 
regression analysis as well as any other variables found to have a p value of <0.05 from the 
univariate Cox regression analyses.  
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CHAPTER FOUR: RESULTS 
4.1 Participant Characteristics 
In total 82 patients were included in this study, several demographic, clinical and PA 
characteristics were either collected for this study or made available from the original database 
from the large previous cohort study.   
4.1.1 Demographic Characteristics 
Included in this study were 32 (39.0%) men and 50 (60.0%) women. The BMI was calculated for 
each patient from the year previous to receiving their ICD. The mean BMI for all patients was 
27.9. Thirty patients (36.6%) were categorized as normal weight, 24 (29.3%) were categorized as 
overweight and 28 (34.1%) were categorized as obese. Smoking status was determined by the 
patients smoking status at the time of their implant. This was categorized as either having never 
smoked or having ever smoked. Thirty four (41.5%) patients reported having smoked at some 
point and 48 (58.5%) of patients reported that they had never smoked. 
4.1.2 Clinical Characteristics  
Extensive clinical variables were collected retrospectively and prospectively for the patients 
from the previous cohort study. To determine disease progression several pre-implant symptoms 
and clinical test results were reviewed.  As mentioned previously patients were only included in 
the current study if they had received an ICD as a PP treatment. The presence of other clinical 
symptoms or abnormal pre-implant clinical test results did not exclude patients. Clinical 
symptoms reviewed included heart palpitations, presyncoope, chest pains and syncope.  
Fifty five (67.1%) patients reported experiencing heart palpitations at the median age of 27 years.  
Forty three (54.4%) patients reported experience presycope at the median age of 29 years. 
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Twenty two (26.8%) patients reported experiencing chest pains at the median age of 31 years. 
Twenty (24.4%) patients reported syncope at the median age of 26 years. 
 
Prior to receiving their ICD patients were required to undergo several clinical tests to monitor 
their heart function. Having an abnormal result on any of the clinical tests may indicate a more 
advanced disease stage. For this study we reviewed the results of four pre-implant clinical tests, 
these tests included 1. 12 lead electrocardiogram (ECG)  2. Signal Averaged electrocardiogram 
(SAECG) 3. A 24 hour Holter Monitor and an 4. Echocardiogram (Echo).  Abnormalities for all 
clinical tests were determined by a physician in the cardiomyopathy clinic and reported in the 
original database. Forty one (50.6%) patients had abnormal 12 lead ECG readings prior to have 
their ICD implanted. Twenty nine (39.7%) had an abnormal SAECG’s, 51 (63.7%) had abnormal 
Holter Monitor results and 42 (55.3%) of the patients had an abnormal Echo (Table 1).  
  
4.1.3 Physical Activity Characteristics  
Using a modified version of the PPAQ patients were asked to retrospectively report their PA 
habits from the year prior to receiving their ICD.  
 
Patients were asked how many times per week they engage in PA that caused their HR to 
increase, 44 (53.7%) of patients reported this occurring more than 3 times per week and 38 
(46.3%)  reported this occurring 3 times per week or less.  Fifty-five (67.1%) of patients reported 
some vigorous activity each week and 27 (32.9%) reported no vigorous activity.  Finally, 37 
(46.3%) patients reported that they were engaging in less than 150 minutes per week of moderate 
to vigorous PA, 14 (17.1%)  patients reported that they were engaging in 150-299 minutes per 
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week of moderate to vigorous activity and 31 (37.8%) patients reported that they were engaging 
in greater than 299 minutes per week of vigorous PA.  
4.1.4 Time to Appropriate Discharge of ICD 
The median age in which the patients received their ICD’s for PP treatment was 35.7 years. 
Twenty eight (34.1%) of the patients had their ICD’s implanted at 30 years or younger, 21 
(25.6%)  had their ICD implanted between the age of 31 and 40, 18 (21.9%)  had their ICD 
implanted between the age of 41 and 50 and 15 (18.3%)  patients had their ICD’s implanted after 
they were 50 years old.  
 
Of the 82 patients included in this study 25 (30.5%) patients experienced an appropriate 
discharge of their ICD at a median age of 36.3 years (Figure 3). 
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Figure 3: Time from receiving ICD to experiencing first appropriate discharge of device. 
 
4.2 Kaplan-Meier Time to Event Analysis 
For this model several survival analyses were preformed to determine if associations existed 
between the various demographic, clinical and PA variables and the amount of time from 
receiving an ICD to the time of the first appropriate discharge of the ICD. The Kaplan Meier 
product limit method was used and a p-value of <0.05 was considered significant. Analyses were 
performed for the four cardiac symptoms; palpitations (Figure 4), pre-syncope (Figure 5), chest 
pain (Figure 6) and syncope (Figure 7), as well as patient age at implant (Figure 8). Additional 
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analyses were performed on the four clinical test results for 12 lead ECG (Figure 9), SAECG 
(Figure 10), Holter monitor (Figure 11), and  Echo (Figure 12) as well as the demographic 
variables of sex (Figure 13), BMI (Figure 14) and Smoking Status (Figure 15). 
 
Finally, tests were performed on three different measures of PA; reported vigorous PA (Figure 
16), reported times per week HR was elevated from PA (Figure 17) and reported weekly minutes 
of moderate to vigorous PA (Figure 18). The variables associated with each Kaplan Meier 
analysis are tabulated in table 1. 
 
In the analysis patients were indicated as censored if they had died, had an appropriate firing of 
their ICD or at the time of their last follow up in clinic. 
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Figure 4: Time to first appropriate discharge of ICD in patients who experienced heart 
palpitations prior to receiving ICD. 
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Figure 5: Time to first appropriate discharge of ICD in patients who experienced pre-syncope 
prior to receiving ICD. 
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Figure 6: Time to first appropriate discharge of ICD in patients who experienced chest pain prior 
to receiving ICD. 
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Figure 7: Time to first appropriate discharge of ICD in patients who experienced syncope prior 
to receiving ICD. 
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Figure 8: Time to first appropriate discharge of ICD by age of patient when ICD was received. 
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Figure 9: Time to first appropriate discharge of ICD in patients who had an abnormal ECG result 
prior to receiving ICD. 
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Figure 10: Time to first appropriate discharge of ICD in patients who had an abnormal SAECG 
result prior to receiving ICD. 
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Figure 11: Time to first appropriate discharge of ICD in patients who had an abnormal 24 hour 
Holter monitor result prior to receiving ICD. 
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Figure 12: Time to first appropriate discharge of ICD in patients who had an abnormal Echo 
result prior to receiving ICD. 
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Figure 13: Time to first appropriate discharge of ICD by sex. 
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Figure 14: Time to first appropriate discharge of ICD by BMI prior to receiving ICD. 
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Figure 15: Time to first appropriate discharge of ICD by smoking status prior to receiving ICD. 
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Figure 16: Time to first appropriate discharge of ICD in patients who reported participating in 
vigorous physical activity.  
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Figure 17: Time to first appropriate discharge of ICD in patients who reported increased heart 
rate from physical activity more than three times per week. 
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Figure 18: Time to first appropriate discharge of ICD by minutes per week of reported moderate 
to vigorous physical activity. 
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All results from the Kaplan-Meier analysis are presented in Table 1. No significant values were 
found for any of the clinical cardiac symptom variables or demographic variables.   
 
For the clinical cardiac variables having an abnormal 24 hour Holter monitor result produced a 
significant result with a log rank p-value of 0.014. The other clinical cardiac variables did not 
produce significant results.  
 
Finally, all three PA variables produced significant results. Having reported some vigorous PA 
produced a p-value of 0.023 and engaging in activities that increase heart greater than 3 times per 
week showed a p-value of 0.009. However participating in higher levels of weekly moderate to 
vigorous PA produced a p-value of 0.000.  
4.3 Cox’s Regression Analysis 
Univariate Cox regression analyses were performed on all covariates and RR was assessed. The 
same four variables produced significant p-values. Having an abnormal 24 hour Holter monitor 
result produced a significant result with a p-value of 0.023 and a RR of 4.1 (CI 1.2-13.7). Having 
reported some vigorous PA produced a p-value of 0.031 and a RR of 3.2 (CI 1.1-9.5).  Engaging 
in activities that increase heart greater than 3 times per week showed a p-value of 0.013 and a 
RR of 3.1 (CI 1.3-7.4). Reporting greater than 300 minutes per week of  moderate to vigorous 
activity produced a p-value of 0.000 with a RR of 12.8 (CI 3.7-45.2). All results are presented in 
Table 1. 
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Table 1: The prevalence of cardiac symptoms, cardiac test abnormalities, demographic data and self-reported physical activity in 
association to appropriate ICD discharge at > 240 beats per minute or death in patients who received an ICD as primary prophylactic 
treatment for ARVC caused by a p.S358L mutation in TMEM43. 
Variable  Category  N* % Number of 
events 
Median time 
to event 
Log rank p 
values 
Cox p 
value 
RR 95% 
CI 
Cardiac symptom          
Palpitations 
 
Yes 55 67.1 19 8.85 0.331 0.335 1.6 0.6-
4.0 
 
 
No 27 32.9 6 -     
Pre-syncope 
 
Yes 43 52.4 14 8.85 0.916 0.916 1.04 0.5-
2.3 
 
 
No 39 47.6 11 -     
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Variable  Category  N* % Number of 
events 
Median time 
to event 
Log rank p 
values 
Cox p 
value 
RR 95% 
CI 
Chest pain 
 
Yes 22 26.8 9 8.85 0.251 0.255 1.6 0.7-
3.7 
 
 
No 60 73.3 16      
Syncope 
 
Yes 20 24.4 4 8.85 0.136 0.146 0.45 0.2-
1.3 
 
 
No 62 75.6 21 -     
Age at implant < 30 
 
28 34.1 8 8.85 0.654 0.667   
 31-40 
 
21 25.6 9 -  0.602 1.3 0.5-
3.4 
 41-50 18 21.9 5 -  0.917 0.94 0.3-
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Variable  Category  N* % Number of 
events 
Median time 
to event 
Log rank p 
values 
Cox p 
value 
RR 95% 
CI 
 2.9 
 > 51 15 18.3 3 -  0.401 0.57 0.1-
2.1 
Clinical cardiac test          
12 lead ECG Normal 
 
40 49.4 10 - 0.651 0.651 1.2 0.5-
2.7 
 Abnormal 
 
41 50.6 15 8.85     
SAECG Normal 
 
44 60.3 9 - 0.069 0.076 2.1 0.9-
5.1 
 2 of 3 criteria 
 
29 39.7 13 6.33     
Holter Monitor Normal 29 36.3 3 - 0.014 0.023 4.1 1.2-
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Variable  Category  N* % Number of 
events 
Median time 
to event 
Log rank p 
values 
Cox p 
value 
RR 95% 
CI 
 13.7 
 > 200 
PVC’s/24hrs 
 
51 63.7 21 8.85     
Echocardiogram Normal 
 
32 44.7 6 - 0.172 0.179 1.9 0.7-
4.9 
 LVE > 2 SD 112% 42 55.3 17 6.56     
 
 
Demographics           
Sex Male 
 
32 39.0 13 6.33 0.051 0.057 2.2 1.0-
4.9 
 Female 50 61.0 12 -     
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Variable  Category  N* % Number of 
events 
Median time 
to event 
Log rank p 
values 
Cox p 
value 
RR 95% 
CI 
 
BMI 
 
Normal 30 36.6 8 - 0.989 0.989   
 Overweight 
 
24 29.3 7 -  0.884 1.1 0.4-
3.0 
 Obese 
 
28 34.1 10 8.85  0.962 1.0 0.4-
2.6 
 
Smoker 
 
 
 
Ever 
 
34 
 
41.5 
 
10 
 
8.85 
 
0.928 
 
0.928 
 
1.0 
 
0.5-
2.3 
 Never 48 58.5 15 -     
Physical Activity          
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Variable  Category  N* % Number of 
events 
Median time 
to event 
Log rank p 
values 
Cox p 
value 
RR 95% 
CI 
Reported weekly vigorous physical  
activity 
 
Yes 55 67.1 21 6.56 0.023 0.031 3.2 1.1-
9.5 
 No 
 
27 32.9 4      
Reported increasing heart rate 
from physical activity 
 
> 3 times per 
week 
 
44 53.7 18 6.56 0.009 0.013 3.1 1.3-
7.4 
 ≤ 3 times per 
week 
 
38 46.3 7 -     
Reported weekly minutes of 
moderate to vigorous physical 
< 150 minutes 
per week 
37 45.1 3 - 0.000    
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Variable  Category  N* % Number of 
events 
Median time 
to event 
Log rank p 
values 
Cox p 
value 
RR 95% 
CI 
activity  
 
 150-299 minutes 
per week 
 
14 17.1 4 -  0.034 5.1 1.1-
23.1 
 ≥ 300 minutes 
per   week 
31 37.8 18 4.95  0.000 12.8 3.7-
45.2 
*
 Frequencies may not total sample size due to missing values                                                   
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For the final model a multivariate Cox regression analysis was performed. This model allowed 
us to control for significant covariates. Sex was also included because of the well-known 
difference in expression of ARVC caused by a p.S358L mutation in TMEM43 in males and 
females. Having an appropriate firing of the ICD was used as the dependent variable. The model 
included male sex, having an abnormal pre-implant 24 Holter monitor result and engaging in 
150-299 minutes/week of moderate to vigorous PA and engaging in greater than 299 
minutes/week of moderate to vigorous PA as the covariates. 
 
All results are presented in Table 3. Significant relationships were found for both male sex and 
abnormal pre-implant 24 hour Holter monitor result with p-values of 0.018 and 0.000 
respectively and RR of 2.9 (CI 1.2-7.0) and 16.4 (CI 3.8-71.5). Engaging in greater than 299 
minutes per week of moderate to vigorous activity showed a strong association with a p- value of 
0.000 and RR of 28.1 (CI 6.9-114.2).  
 
This model suggests that when controlling for sex and having an abnormal pre-implant 24 hour 
Holter monitor result, patients with ARVC caused by a p.S358L mutation in TMEM43 who 
engage in moderate to vigorous PA greater than 299 minutes per week are significantly more 
likely to experience an appropriate firing of their ICD when compared to patients who do not.  
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Table 2: Multivariate cox’s regression analysis of covariates associated with appropriate ICD 
discharge at > 240 beats per minute or death in patients who received an ICD as primary 
prophylactic treatment for ARVC caused by a p.S358L mutation in TMEM43. 
Covariates 
 
Category  Cox p value RR 95% CI 
Sex Male 
 
0.018 2.9 1.2-7.0 
Holter Monitor > 200 PVC’s/24hrs 
 
0.000 16.4 3.8-71.5 
Reported weekly 
minutes of 
moderate to 
vigorous physical 
activity  
 
150-299 minutes 
per week 
 
0.061 4.9 0.9-25.9 
 >300 minutes per 
week 
0.000 28.1 6.9-114.2 
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CHAPTER FIVE: DISCUSSION 
5.1 Overview of Results 
This cross sectional study sought to determine if an association existed between retrospectively 
self-reported PA and the onset and progression of ARVC caused by a p.S358L mutation in 
TMEM43. Several clinical cardiac symptoms, cardiac test abnormalities and demographic 
variables from time of ICD implant were also examined to determine their association with time 
to appropriate ICD discharge.  
5.1.1 Time to Event Analyses  
For our study, first appropriate discharge of the ICD at any rate for sustained VT or at VT > 240 
bpm was used as the measurement to indicate advanced disease stage or phenotypic expression 
of ARVC caused by a p.S358L mutation in TMEM43, as such time to the first appropriate 
discharge of the ICD was used as the dependent variable in our Kaplan-Meier time to event 
analyses and our Cox regression analyses. Previous research in this same population indicated 
that appropriate discharge of the ICD could be considered an event analogous to aborted death 
[13], and therefore an appropriate indicator of phenotypic expression of ARVC caused by a 
p.S358L mutation in TMEM43. 
 
Data on several clinical cardiac symptoms prior to implantation of the patients ICD’s was well 
documented and reported for this population. Information was available on both the presence of 
clinical symptoms as well at the age in which clinical symptoms presented. The four clinical 
symptoms evaluated in this study included heart palpitations, pre-syncope, chest pain and 
syncope.  The presence or absence of each the clinical symptoms were used as explanatory 
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variables in Kaplan-Meier and Cox regression analyses. None of the clinical symptom variables 
used in this study were shown to be predictive of time to appropriate discharge of the ICD. This 
result is not surprising because with this form of ARVC patients may be in the concealed phase 
of the disease with no evidence of clinical symptoms but still be at a high risk of a cardiac event. 
Previous research on this population showed that many patients are asymptomatic and that 
without appropriate ICD therapy, the first presenting symptom in many cases maybe SCD [15]. 
None of the clinical cardiac symptoms were used in the final multivariate Cox regression 
analysis. 
 
Data was also available on the results of several clinical cardiac test results preformed prior to 
implantation of the ICD. Of the four clinical cardiac test results that were examined only one test 
abnormality was associated with time to appropriate discharge of the ICD. Having evidence of 
greater than 200 PVC’s on a 24 hour Holter monitor prior ICD implantations was shown to be 
significantly associated with time to first appropriate firing of the ICD.  Earlier studies,  in this 
same population, showed that ectopy (a disturbance of the cardiac rhythm ) occurred early in the 
natural history of the disease [16] and that having an  abnormal 24 hour Holter monitor results of 
PVC’s >200 was the earliest sign of disease manifestation in both sexes. 
 
In this same population in a multivariate Cox regression analysis showed that having an 
abnormal 24 hour Holter monitor result prior to ICD implantation was the only significant 
independent predictor of appropriate firing of ICD when compared to other clinical test 
result[13]. Because it was found to be a significant predictor of time to appropriate discharge of 
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the ICD in both the Kaplan-Meier and Cox regression analysis having an abnormal 24 hour 
Holter monitor result prior to receiving an ICD was used in the final Cox regression analysis. 
 
Three demographic variables from the patients prior to receiving their ICD’s were also analyzed 
with Kaplan-Meier and Cox regression analyses to see if they were associated with time to first 
appropriate firing of the ICD. These included sex, if they had ever smoked or not and BMI, 
categorized as normal weight, overweight and obese. No demographic variables were associated 
with time to first appropriate firing of the ICD. However, sex was nearly significant with 
Kaplan-Meier and Cox regression analyses producing p-values of 0.051 and 0.058 and a RR of 
2.1 (CI 1.0-4.9). Much of this data used males who had died, so limiting analyses to those with 
an ICD introduces a survivor bias: only males alive can be treated. So based upon the clear sex 
influence of this mutation documented, many times, sex was included in the final multivariate 
Cox regression analyses [3, 15, 16].  
 
Finally three different measurements of PA were evaluated to determine if an association existed 
between patient PA levels prior to receiving their ICD and time to first appropriate firing of the 
ICD.  All PA variables were derived from patient reported responses to the PPAQ. One question 
reported if patients had participated in any weekly vigorous activity. The second question 
reported how often patients report participating in PA which increased their HR, separated in to 
greater than 3 times per week or less than or equal to 3 times per week. The final question 
reported how many minutes per patients participated in moderate to vigorous activity. This 
question was divided in to 3 categories based on whether patients were not meeting, meeting or 
exceeding current PA recommendations for optimal health benefits [17, 38, 40]. Kaplan-Meier 
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and Cox regression analyses found all three measurements of PA to be associated to time to first 
appropriate firing of the ICD. The strongest association was found with the variable reporting the 
number of minutes per week patients reported participating in moderate to vigorous PA with p-
values of 0.000 in both analyses and produced a RR of 5.1 (CI 1.1-23.1) in the group meeting 
current PA guidelines and a RR of 12.8 (CI 3.7-45.2) in the group exceeding current PA 
guidelines. 
 
The final multivariate Cox regression analysis included male sex, having evidence of venticular 
ectopy as determined by have a pre-ICD implant 24 hour Holter monitor test showing PVC’s > 
200 and both meeting and exceeding current PA guidelines for moderate to vigorous activity 
(reporting 150-299 minutes per week and > 300 minutes per week respectably). The final results 
showed having preexisting venticular ectopy and reporting participating in >300 minutes per 
week of moderate to vigorous activity to be strongly associated with time to first appropriate 
discharge of the ICD with RR’s of 16.4 (CI 3.8-71.5) and 28.1 (CI 6.9-114.2). 
 
It should be noted that 58% (18/31) of patients who reported participating in >300 minutes per 
week of moderate to vigorous PA experienced an appropriate discharges of their ICD, while only 
8% (3/37) patients who reported participating in <150 minutes per week of moderate to vigorous 
PA experienced an appropriate discharges of their ICD. Additionally, the three patients who 
reported the most minutes per week of moderate to vigorous PA all experienced an appropriate 
discharge of their ICD’s.    
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The results of this study are consistent with two previous studies. One involving 87 ARVC 
patients with four different desmosome mutations carriers [60] and another involving 110 ARVC 
patients with eight different pathogenic mutations [61], thus to date this is the largest study of its 
kind involving a patients with the same ARVC genetic mutation. 
  
5.2 Clinical Implications 
The results from this study may be very clinically important.  Our results show strong evidence 
between PA and the phenotypic expression of ARVC caused by a p.S358L mutation in 
TMEM43. In the largest, genetically homogeneous, study to date we found high levels of weekly 
moderate to vigorous activity prior to receiving an ICD as PP treatment to be strongly associated 
with the time to first appropriate discharge of the ICD. The risk remained high even when the 
previously identified risk factors of evidence of ventricular ectopy and male sex were controlled 
for. 
 
This data suggests that guidelines should be created to advise affected individuals about the risks 
associated with participating in high levels of moderate to vigorous PA. Similar guidelines for 
participation in recreation and leisure time PA have already been created for other genetic 
cardiovascular diseases [76, 77], but may need to be modified for this population.  
 
Despite current PA guidelines for optimal health benefits [38] patients with ARVC caused by a 
p.S358L mutation in TMEM43 should be cautioned to avoid prolonged periods of high intensity 
PA.   
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Modifying their PA habits could significantly influence the progression and expression of ARVC 
caused by a p.S358L mutation in TMEM43. 
5.3 Study Limitations 
5.3.1 Physical Activity Measurement  
Using a retrospective interview based PA questionnaire may have had an impact on our study 
findings. Patients were asked to report PA habits from prior to having their ICD implanted; as 
such our measurement of PA relied heavily on the patient’s ability to recall past PA habits. This 
inherently introduced error in the form of recall bias which could have an impact on the accuracy 
of the reported data [78].  
 
The questionnaire used in this study, the PPAQ, was originally designed to measure recreational 
and leisure time activities that are often more likely to be moderate to vigorous in nature 
[25].With this being the case, daily, lighter intensity activities, such as occupational and 
household activities are more likely  to be excluded or under reported [22]. This questionnaire 
relied heavily on what activities the patients considered to be PA.  
 
Additionally, because of the many well-known health benefits of PA our patients may have been 
more inclined to over report their PA habits to appear more socially desirable, creating a social 
desirability bias [78, 79]. 
 
For a more accurate measure of PA future studies could follow patients prospectively for a 
specified period of time and use accelerometers to objectively measure weekly PA [80]. 
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5.3.2 Generalizability  
Our results pertain only to ARVC caused by a p.S358L mutation in TMEM43 in patients who 
received their ICD as a PP treatment therefore these results may not apply to other mutation 
carriers or be generalizable to other forms of ARVC with different mutations. 
5.4 Study Strengths 
5.4.1 Cohort Data 
This study had the benefit of utilizing a detailed dataset collected from a large previously 
established genetically homogenous cohort. The extensive data for this cohort was collected both 
retrospectively and prospectively, spanning several generations. The gene responsible for this 
form of ARVC has been identified, allowing for all mutation carriers to be accurately diagnosed 
and identified through genetic testing. As such, this unique population from Newfoundland, 
Canada has been described as the largest single well characterized subtype of ARVC in the 
world [13]. The patients in this study have been followed by the same cardiac care team and 
nearly all decisions regarding ICD therapy were made by the same electrophysiologist in St. 
John’s, Newfoundland. While this type of ARVC is most common in Newfoundland, Canada it 
is also present in other populations.    
 
Nearly all previous research on PA and ARVC has focused on ARVC involving desmosome 
mutations. While our results have shown to be consistent with other studies involving patients 
with several different forms of ARVC [60, 61] our study is the largest study of its kind involving 
patients with the same ARVC genetic mutation and the only study that has examined ARVC 
caused by a p.S358L mutation in TMEM43 specifically.  
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5.4.2 Physical Activity Measurement 
The PPAQ used in this study is one of the most commonly used questionnaires to measure PA in 
epidemiological studies [25]. Its reliability and validity has been continuously evaluated [22, 81, 
82]. Studies have shown that typically participants more accurately report their moderate and 
vigorous PA [83]. When compared to objective accelerometer measurements the PPAQ provided 
similar estimates of moderate and vigorous activity [22] confirming it as a useful tool to assess 
weekly levels of moderate and vigorous activity. Because current PA guidelines provide 
recommendations for how much weekly moderate to vigorous PA is needed for optimal health 
benefits we were specifically interested in accessing the patients levels of weekly moderate to 
vigorous PA. 
 
This study had the added advantage of all questionnaires being administered either in person or 
over the phone by the same investigator. This allowed for the questionnaire to be administered in 
a consistent fashion. It also gave patients the opportunity to ask questions and receive 
clarification if needed. Having the same interviewer administer questionnaires can improve the 
overall accuracy of the questionnaire [84]. 
5.5 Future Research  
5.5.1 Pathogenic Pathways 
Nearly all previous research investigating PA and ARVC has focused on forms of ARVC 
involving desmosomal mutations however this study has shown a strong association between PA 
and the progression of ARVC caused by a p.S358L mutation in TMEM43, a transmembrane 
protein. While our results have shown to be consistent with the desmosomal mutation studies 
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future research could involve examining the more specific pathogenic pathways which link 
ARVC caused by a p.S358L mutation in TMEM43 and PA. The TMEM43 gene has been found 
be one of the many target genes of PPARγ, an adipogenic transcription factor [65] and PA has 
shown to generate PPARγ lignands [66] which activate PPARγ signaling. The increased PPARγ 
signaling, generated during PA, combined with the dysregulation of the PPARγ pathway from 
the p.S358L mutation in TMEM43 could contribute to accelerated fibrofatty replacement of the 
right ventricle in patients who are more physically active, thus promoting phenotypic expression.   
5.5.2 Other Modifiable Risk Factors  
Nearly two decades of research have been devoted to defining and identifying ARVC caused by 
a p.S358L mutation in TMEM43 in Newfoundland, Canada. The exact gene responsible for this 
disease has been discovered [3] allowing for early diagnosis and treatment in affected 
individuals. This type of ARVC has been shown to be highly variable in its phenotypic 
expression and the current study showed that progression and expression of ARVC caused by a 
p.S358L mutation in TMEM43 can be influenced when affected individuals participate in high 
levels of moderate to vigorous PA. This study suggests that PA is a modifiable risk factor that 
could be adjusted to decrease the burden this disease and improve outcomes. Future research 
could investigate the role other environmental and modifiable risk factors may have on the 
progression and expression of ARVC caused by a p.S358L mutation in TMEM43.  
5.5 Conclusion  
This study showed a strong association between patients who reported participating in a high 
level of weekly moderate to vigorous PA and the development and expression of ARVC caused 
by a p.S358L mutation in TMEM43. This association was found to be independent of the 
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previously established risk factors of male sex and ventricular ectopy prior to receiving an ICD 
for PP treatment. This association suggests that moderate to vigorous PA may play a role in 
promoting progression of this disease.   
 
Minimizing participation in high levels of weekly moderate to vigorous PA may be important for 
patients diagnosed with ARVC caused by a p.S358L mutation in TMEM43 and could play a role 
in minimizing adverse outcomes associated with the disease. New guidelines should be created 
to advise patients with ARVC caused by a p.S358L mutation in TMEM43 on safe PA 
recommendations.  
 
Because of the high variability in the phenotypic expression of ARVC caused by a p.S358L 
mutation in TMEM43 future research must continue to examine the how genetic and 
environmental factors interact and influence progression and expression of this disease.   
  
77 
 
REFERENCES 
1. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H, 
Corrado D, Cox MG, Daubert JP et al: Diagnosis of arrhythmogenic right ventricular 
cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur 
Heart J 2010, 31:806-814. 
 
2. Gemayel C, Pelliccia A, Thompson PD: Arrhythmogenic right ventricular 
cardiomyopathy. Journal of the American College of Cardiology 2001, 38(7):1773-
1781. 
 
3. Merner ND, Hodgkinson KA, Haywood AF, Connors S, French VM, Drenckhahn JD, 
Kupprion C, Ramadanova K, Thierfelder L, McKenna W et al: Arrhythmogenic right 
ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder 
caused by a missense mutation in the TMEM43 gene. Am J Hum Genet 2008, 82:809-
821. 
 
4. Maron BJ, Chaitman BR, Ackerman MJ, Bayés de Luna A, Corrado D, Crosson JE, Deal 
BJ, Driscoll DJ, Estes NAM, Araújo CGS et al: Recommendations for Physical 
Activity and Recreational Sports Participation for Young Patients With Genetic 
Cardiovascular Diseases. Circulation 2004, 109(22):2807-2816. 
 
5. Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G: Does sports activity enhance 
the risk of sudden death in adolescents and young adults? Journal of the American 
College of Cardiology 2003, 42(11):1959-1963 
. 
6. Maron BJ: Sudden death in young athletes. N Engl J Med 2003, 349:1064-1075. 
 
7. Kirchhof P, Fabritz L, Zwiener M, Witt H, Schafers M, Zellerhoff S, Paul M, Athai T, 
Hiller KH, Baba HA et al: Age- and training-dependent development of 
arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-
deficient mice. Circulation 2006, 114:1799-1806. 
 
8. Fisher NG, Gilbert TJ: Arrhythmogenic right ventricular dysplasia. An illustrated 
review highlighting developments in the diagnosis and management of this 
potentially fatal condition. Postgraduate medical journal 2000, 76(897):395-398. 
 
9. Basso C, Corrado D, Marcus FI, Nava A, Thiene G: Arrhythmogenic right ventricular 
cardiomyopathy. Lancet (London, England) 2009, 373(9671):1289-1300. 
 
10. Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C, 
Grosgogeat Y: Right ventricular dysplasia: a report of 24 adult cases. Circulation 
1982, 65(2):384-398. 
 
11. Sen-Chowdhry S, Syrris P, McKenna WJ: Genetics of right ventricular 
cardiomyopathy. J Cardiovasc Electrophysiol 2005, 16:927-935. 
78 
 
12. Corrado D, Wichter T, Link MS, Hauer RN, Marchlinski FE, Anastasakis A, Bauce B, 
Basso C, Brunckhorst C, Tsatsopoulou A et al: Treatment of Arrhythmogenic Right 
Ventricular Cardiomyopathy/Dysplasia: An International Task Force Consensus 
Statement. Circulation 2015, 132(5):441-453. 
 
13. Hodgkinson KA, Howes AJ, Boland P, Shen XS, Stuckless S, Young TL, Curtis F, 
Collier A, Parfrey PS, Connors SP: Long-Term Clinical Outcome of Arrhythmogenic 
Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in 
TMEM43 Following Implantable Cardioverter Defibrillator Therapy. Circ Arrhythm 
Electrophysiol 2016, 9. 
 
14. Rahman P, Jones A, Curtis J, Bartlett S, Peddle L, Fernandez BA, Freimer NB: The 
Newfoundland population: a unique resource for genetic investigation of complex 
diseases. Hum Mol Genet 2003, 12 Spec No 2:R167-172. 
 
15. Hodgkinson KA, Parfrey PS, Bassett AS, Kupprion C, Drenckhahn J, Norman MW, 
Thierfelder L, Stuckless SN, Dicks EL, McKenna WJ et al: The impact of implantable 
cardioverter-defibrillator therapy on survival in autosomal-dominant 
arrhythmogenic right ventricular cardiomyopathy (ARVD5). J Am Coll Cardiol 
2005, 45:400-408. 
 
16. Hodgkinson KA, Connors SP, Merner N, Haywood A, Young TL, McKenna WJ, 
Gallagher B, Curtis F, Bassett AS, Parfrey PS: The natural history of a genetic subtype 
of arrhythmogenic right ventricular cardiomyopathy caused by a p.S358L mutation 
in TMEM43. Clin Genet 2013, 83:321-331. 
 
17. World Health Organization: Global Recommendations on Physical Activity for 
Health. In. Geneva, Switzerland: World Health Organization; 2010. 
 
18. Caspersen CJ, Powell KE, Christenson GM: Physical activity, exercise, and physical 
fitness: definitions and distinctions for health-related research. Public health reports 
(Washington, DC : 1974) 1985, 100(2):126-131. 
 
19. Mahabir S, Baer DJ, Giffen C, Clevidence BA, Campbell WS, Taylor PR, Hartman TJ: 
Comparison of energy expenditure estimates from 4 physical activity questionnaires 
with doubly labeled water estimates in postmenopausal women. The American 
journal of clinical nutrition 2006, 84(1):230-236. 
 
20. LaPorte RE, Montoye HJ, Caspersen CJ: Assessment of physical activity in 
epidemiologic research: problems and prospects. Public health reports (Washington, 
DC : 1974) 1985, 100(2):131-146. 
 
21. Washburn RA, Goldfield SR, Smith KW, McKinlay JB: The validity of self-reported 
exercise-induced sweating as a measure of physical activity. American journal of 
epidemiology 1990, 132(1):107-113. 
79 
 
22. Strath SJ, Bassett DR, Jr., Swartz AM: Comparison of the college alumnus 
questionnaire physical activity index with objective monitoring. Annals of 
epidemiology 2004, 14(6):409-415. 
 
23. Papathanasiou G, Georgoudis G, Georgakopoulos D, Katsouras C, Kalfakakou V, 
Evangelou A: Criterion-related validity of the short International Physical Activity 
Questionnaire against exercise capacity in young adults. European journal of 
cardiovascular prevention and rehabilitation : official journal of the European Society of 
Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation 
and Exercise Physiology 2010, 17(4):380-386. 
 
24. Bassett DR, Vachon JA, Kirkland AO, Howley ET, Duncan GE, Johnson KR: Energy 
cost of stair climbing and descending on the college alumnus questionnaire. Medicine 
and science in sports and exercise 1997, 29(9):1250-1254. 
 
25. Paffenbarger RS, Jr., Wing AL, Hyde RT: Physical activity as an index of heart attack 
risk in college alumni. American journal of epidemiology 1978, 108(3):161-175. 
 
26. Crouter SE, Churilla JR, Bassett DR, Jr.: Estimating energy expenditure using 
accelerometers. European journal of applied physiology 2006, 98(6):601-612. 
 
27. McDonough JR, Kusumi F, Bruce RA: Variations in maximal oxygen intake with 
physical activity in middle-aged men. Circulation 1970, 41(5):743-751. 
 
28. Ainsworth BE, Haskell WL, Leon AS, Jacobs DR, Jr., Montoye HJ, Sallis JF, 
Paffenbarger RS, Jr.: Compendium of physical activities: classification of energy costs 
of human physical activities. Medicine and science in sports and exercise 1993, 
25(1):71-80. 
 
29. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, O'Brien WL, 
Bassett DR, Jr., Schmitz KH, Emplaincourt PO et al: Compendium of physical 
activities: an update of activity codes and MET intensities. Medicine and science in 
sports and exercise 2000, 32(9 Suppl):S498-504. 
 
30. Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR, Jr., Tudor-Locke C, 
Greer JL, Vezina J, Whitt-Glover MC, Leon AS: 2011 Compendium of Physical 
Activities: a second update of codes and MET values. Medicine and science in sports 
and exercise 2011, 43(8):1575-1581. 
 
31. Passmore R, Durnin JV: Human energy expenditure. Physiological reviews 1955, 
35(4):801-840. 
 
32. Jette M, Sidney K, Blumchen G: Metabolic equivalents (METS) in exercise testing, 
exercise prescription, and evaluation of functional capacity. Clinical cardiology 1990, 
13(8):555-565. 
80 
 
33. Fletcher GF, Balady GJ, Amsterdam EA, Chaitman B, Eckel R, Fleg J, Froelicher VF, 
Leon AS, Pina IL, Rodney R et al: Exercise standards for testing and training: a 
statement for healthcare professionals from the American Heart Association. 
Circulation 2001, 104:1694-1740. 
 
34. National Center for Chronic Disease P, Health P: Physical Activity and Health: A 
Report of the Surgeon General. In. Washington, D.C., USA; 1996. 
 
35. Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C, Buchner D, Ettinger 
W, Heath GW, King AC: Physical activity and public health. A recommendation 
from the Centers for Disease Control and Prevention and the American College of 
Sports Medicine. Jama 1995, 273:402-407. 
 
36. Medicine ACoS, Franklin BA, Whaley MH, Howley ET, Balady GJ: ACSM's 
Guidelines for Exercise Testing and Prescription: Lippincott Williams & Wilkins; 
2000. 
 
37. National Center for Chronic Disease Prevention and Health Promotion: Physical Activity 
and Health: A Report of the Surgeon General. In. Washington, D.C., USA; 1996. 
 
38. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, Nieman DC, 
Swain DP: American College of Sports Medicine position stand. Quantity and 
quality of exercise for developing and maintaining cardiorespiratory, 
musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for 
prescribing exercise. Medicine and science in sports and exercise 2011, 43(7):1334-
1359. 
 
39. U.S. Department of Health and Human Services: 2008 Physical Activity Guidelines for 
Americans In. Washington, D.C., United States; 2008. 
 
40. Canadian Society for Exercise Physiology: Canadian Physical Activity and Sedentary 
Behaviour Guidelines. In. Ottawa, Canada: Canadian Society for Exercise Physiology 
2013. 
 
41. Maron BJ: Sudden death in young athletes. The New England journal of medicine 
2003, 349(11):1064-1075. 
 
42. Bauce B, Frigo G, Benini G, Michieli P, Basso C, Folino AF, Rigato I, Mazzotti E, 
Daliento L, Thiene G et al: Differences and similarities between arrhythmogenic right 
ventricular cardiomyopathy and athlete's heart adaptations. British journal of sports 
medicine 2010, 44(2):148-154. 
 
43. La Gerche A, Connelly KA, Mooney DJ, MacIsaac AI, Prior DL: Biochemical and 
functional abnormalities of left and right ventricular function after ultra-endurance 
exercise. Heart (British Cardiac Society) 2008, 94(7):860-866. 
81 
 
44. Heidbuchel H, Hoogsteen J, Fagard R, Vanhees L, Ector H, Willems R, Van Lierde J: 
High prevalence of right ventricular involvement in endurance athletes with 
ventricular arrhythmias. Role of an electrophysiologic study in risk stratification. 
European heart journal 2003, 24(16):1473-1480. 
 
45. Elmaghawry M, Alhashemi M, Zorzi A, Yacoub MH: A global perspective of 
arrhythmogenic right ventricular cardiomyopathy. Global cardiology science & 
practice 2012, 2012(2):81-92. 
 
46. Arsenault D: Bedford hockey player dies during QMJHL camp in N.B. In: The 
Chronicle Herald. Halifax, Nova Scotia; 2013. 
 
47. Gilbert A, Murphy, B.: Jordan Boyd's parents call for more medical screening. In: 
CBC News. May 22 edn. Nova Scotia, Canada; 2014. 
 
48. Corrado D, Thiene G, Nava A, Rossi L, Pennelli N: Sudden death in young competitive 
athletes: clinicopathologic correlations in 22 cases. The American journal of medicine 
1990, 89(5):588-596. 
 
49. Nava A, Thiene G, Canciani B, Scognamiglio R, Daliento L, Buja G, Martini B, Stritoni 
P, Fasoli G: Familial occurrence of right ventricular dysplasia: a study involving 
nine families. J Am Coll Cardiol 1988, 12(5):1222-1228. 
 
50. Basso C, Thiene G, Corrado D, Angelini A, Nava A, Valente M: Arrhythmogenic right 
ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? Circulation 
1996, 94(5):983-991. 
 
51. Rampazzo A, Nava A, Danieli GA, Buja G, Daliento L, Fasoli G, Scognamiglio R, 
Corrado D, Thiene G: The gene for arrhythmogenic right ventricular 
cardiomyopathy maps to chromosome 14q23-q24. Hum Mol Genet 1994, 3(6):959-
962. 
 
52. Nava A, Bauce B, Basso C, Muriago M, Rampazzo A, Villanova C, Daliento L, Buja G, 
Corrado D, Danieli GA et al: Clinical profile and long-term follow-up of 37 families 
with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2000, 
36(7):2226-2233. 
 
53. Furlanello F, Bettini R, Bertoldi A, Vergara G, Visona L, Durante GB, Inama G, Frisanco 
L, Antolini R, Zanuttini D: Arrhythmia patterns in athletes with arrhythmogenic 
right ventricular dysplasia. Eur Heart J 1989, 10 Suppl D:16-19. 
 
54. de Noronha SV, Sharma S, Papadakis M, Desai S, Whyte G, Sheppard MN: Aetiology of 
sudden cardiac death in athletes in the United Kingdom: a pathological study. Heart 
2009, 95(17):1409-1414. 
 
82 
 
55. MacRae CA, Birchmeier W, Thierfelder L: Arrhythmogenic right ventricular 
cardiomyopathy: moving toward mechanism. J Clin Invest 2006, 116:1825-1828. 
 
56. Pilichou K, Nava A, Basso C, Beffagna G, Bauce B, Lorenzon A, Frigo G, Vettori A, 
Valente M, Towbin J et al: Mutations in desmoglein-2 gene are associated with 
arrhythmogenic right ventricular cardiomyopathy. Circulation 2006, 113:1171-1179. 
 
57. Rampazzo A, Nava A, Malacrida S, Beffagna G, Bauce B, Rossi V, Zimbello R, 
Simionati B, Basso C, Thiene G et al: Mutation in human desmoplakin domain 
binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular 
cardiomyopathy. Am J Hum Genet 2002, 71:1200-1206. 
 
58. Gerull B, Heuser A, Wichter T, Paul M, Basson CT, McDermott DA, Lerman BB, 
Markowitz SM, Ellinor PT, MacRae CA et al: Mutations in the desmosomal protein 
plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. 
Nat Genet 2004, 36:1162-1164. 
 
59. McKoy G, Protonotarios N, Crosby A, Tsatsopoulou A, Anastasakis A, Coonar A, 
Norman M, Baboonian C, Jeffery S, McKenna WJ: Identification of a deletion in 
plakoglobin in arrhythmogenic right ventricular cardiomyopathy with 
palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 2000, 355:2119-
2124. 
 
60. James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, Tedford RJ, Judge 
DP, Calkins H: Exercise increases age-related penetrance and arrhythmic risk in 
arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal 
mutation carriers. Journal of the American College of Cardiology (JACC) 2013, 
62(14):1290-1297. 
 
61. Saberniak J, Hasselberg NE, Borgquist R, Platonov PG, Sarvari SI, Smith HJ, Ribe M, 
Holst AG, Edvardsen T, Haugaa KH: Vigorous physical activity impairs myocardial 
function in patients with arrhythmogenic right ventricular cardiomyopathy and in 
mutation positive family members. European journal of heart failure 2014, 
16(12):1337-1344. 
 
62. Basso C, Corrado D, Bauce B, Thiene G: Arrhythmogenic right ventricular 
cardiomyopathy. Circulation Arrhythmia and electrophysiology 2012, 5(6):1233-1246. 
 
63. Garcia-Gras E, Lombardi R, Giocondo MJ, Willerson JT, Schneider MD, Khoury DS, 
Marian AJ: Suppression of canonical Wnt/beta-catenin signaling by nuclear 
plakoglobin recapitulates phenotype of arrhythmogenic right ventricular 
cardiomyopathy. J Clin Invest 2006, 116:2012-2021. 
 
64. Fujimaki S, Hidaka R, Asashima M, Takemasa T, Kuwabara T: Wnt protein-mediated 
satellite cell conversion in adult and aged mice following voluntary wheel running. J 
Biol Chem 2014, 289:7399-7412. 
83 
 
65. Lemay DG, Hwang DH: Genome-wide identification of peroxisome proliferator 
response elements using integrated computational genomics. Journal of lipid research 
2006, 47(7):1583-1587. 
 
66. Thomas AW, Davies NA, Moir H, Watkeys L, Ruffino JS, Isa SA, Butcher LR, Hughes 
MG, Morris K, Webb R: Exercise-associated generation of PPARgamma ligands 
activates PPARgamma signaling events and upregulates genes related to lipid 
metabolism. Journal of applied physiology (Bethesda, Md : 1985) 2012, 112(5):806-815. 
 
67. Petridou A, Tsalouhidou S, Tsalis G, Schulz T, Michna H, Mougios V: Long-term 
exercise increases the DNA binding activity of peroxisome proliferator-activated 
receptor gamma in rat adipose tissue. Metabolism: clinical and experimental 2007, 
56(8):1029-1036. 
 
68. Davies NA, Watkeys L, Butcher L, Potter S, Hughes MG, Moir H, Morris K, Thomas 
AW, Webb R: The contributions of oxidative stress, oxidised lipoproteins and 
AMPK towards exercise-associated PPARgamma signalling within human 
monocytic cells. Free radical research 2015, 49(1):45-56. 
 
69. Hey-Mogensen M, Hojlund K, Vind BF, Wang L, Dela F, Beck-Nielsen H, Fernstrom M, 
Sahlin K: Effect of physical training on mitochondrial respiration and reactive 
oxygen species release in skeletal muscle in patients with obesity and type 2 diabetes. 
Diabetologia 2010, 53(9):1976-1985. 
 
70. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM: 
PPARgamma signaling and metabolism: the good, the bad and the future. Nature 
medicine 2013, 19(5):557-566. 
 
71. Pinski SL, Fahy GJ: Implantable cardioverter-defibrillators. The American journal of 
medicine 1999, 106(4):446-458. 
 
72. Lee I, Paffenbarger RS, Jr.: Physical activity and stroke incidence: the Harvard 
Alumni Health Study. Stroke (00392499) 1998, 29(10):2049-2054. 
 
73. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera CA, Heath 
GW, Thompson PD, Bauman A: Physical activity and public health: updated 
recommendation for adults from the American College of Sports Medicine and the 
American Heart Association. Circulation 2007, 116(9):1081-1093. 
 
74. Breithardt G, Cain ME, el-Sherif N, Flowers NC, Hombach V, Janse M, Simson MB, 
Steinbeck G: Standards for analysis of ventricular late potentials using high-
resolution or signal-averaged electrocardiography: a statement by a task force 
committee of the European Society of Cardiology, the American Heart Association, 
and the American College of Cardiology. Journal of the American College of 
Cardiology 1991, 17(5):999-1006. 
84 
 
75. Henry WL, Gardin JM, Ware JH: Echocardiographic measurements in normal 
subjects from infancy to old age. Circulation 1980, 62(5):1054-1061. 
 
76. Maron BJ, Zipes DP: Introduction: eligibility recommendations for competitive 
athletes with cardiovascular abnormalities-general considerations. Journal of the 
American College of Cardiology 2005, 45(8):1318-1321. 
 
77. Maron BJ, Chaitman BR, Ackerman MJ, Bayes de Luna A, Corrado D, Crosson JE, Deal 
BJ, Driscoll DJ, Estes NA, 3rd, Araujo CG et al: Recommendations for physical 
activity and recreational sports participation for young patients with genetic 
cardiovascular diseases. Circulation 2004, 109(22):2807-2816. 
 
78. Sallis JF, Saelens BE: Assessment of physical activity by self-report: status, 
limitations, and future directions. Research quarterly for exercise and sport 2000, 71(2 
Suppl):S1-14. 
 
79. Aadahl M, Kjaer M, Kristensen JH, Mollerup B, Jorgensen T: Self-reported physical 
activity compared with maximal oxygen uptake in adults. European journal of 
cardiovascular prevention and rehabilitation : official journal of the European Society of 
Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation 
and Exercise Physiology 2007, 14(3):422-428. 
 
80. Lee IM, Shiroma EJ: Using accelerometers to measure physical activity in large-scale 
epidemiological studies: issues and challenges. British journal of sports medicine 2014, 
48(3):197-201. 
 
81. Ainsworth BE, Leon AS, Richardson MT, Jacobs DR, Paffenbarger RS, Jr.: Accuracy of 
the College Alumnus Physical Activity Questionnaire. Journal of clinical 
epidemiology 1993, 46(12):1403-1411. 
 
82. Lee IM, Paffenbarger RS, Jr.: Associations of light, moderate, and vigorous intensity 
physical activity with longevity. The Harvard Alumni Health Study. American 
journal of epidemiology 2000, 151(3):293-299. 
 
83. Wareham NJ, Rennie KL: The assessment of physical activity in individuals and 
populations: why try to be more precise about how physical activity is assessed? Int 
J Obes Relat Metab Disord 1998, 22 Suppl 2:S30-38. 
 
84. Okamoto K, Ohsuka K, Shiraishi T, Hukazawa E, Wakasugi S, Furuta K: Comparability 
of epidemiological information between self- and interviewer-administered 
questionnaires. Journal of clinical epidemiology 2002, 55(5):505-511. 
85 
 
APPENDICES 
APPENDIX A 
 1994 Task Force Criteria 2010 Task Force Criteria 
 
2 major, 1 major + 2 minor, or 4 minor 
 
Definite = 2 major OR 1 major + 2 minor 
Borderline = 1 major + 1 minor OR 3 minor 
Possible = 1 major OR 2 minor 
 
Criteria I. Global/regional dysfunction/structural alterations 
 
Major  
• Severe dilatation and reduction of RVEF 
w/no (or only mild) LV impairment 
• Localized RV aneurysms (akinetic or 
dyskinetic areas w/diastolic bulging) 
• Severe segmental dilatation of the RV 
 
• Regional RV akinesis, dyskinesia, or aneurysm 
• and 1 of the following (end diastole): 
____PLAX RVOT ≥32 mm (correct for body size [PLAX/BSA] ≥19 mm/m2 
____PSAX RVOT ≥36 mm (correct for body size [PSAX/BSA] ≥21 mm/m2) 
____or fractional area change ≤33% 
By MRI: 
• Regional RV akinesia or dyskinesia or dyssynchronous RV contraction 
• and 1 of the following : 
____Ratio of RV end-diast vol to BSA ≥110 mL/m2 (male) or ≥100 mL/m2 
(female) 
____or RV ejection fraction ≤40% 
By RV Angiography: 
• Regional RV akinesia, dyskinesia, or aneurysm 
 
Minor  
• Mild global RV dilatation and/or EF 
reduction with normal LV 
• Mild segmental dilatation of the RV 
• Regional RV hypokinesia 
 
 
 
By 2D Echo: 
• Regional RV akinesia or dyskinesia 
• and 1 of the following (end diastole): 
___PLAX RVOT ≥29 to <32 mm (correct body size PLAX/BSA ≥16 to <19 
mm/m2) 
___PSAX RVOT ≥32 to <36 mm (correct body size [PSAX/BSA] ≥18 to <21 
mm/m2) 
___or fractional area change >33% to ≤40% 
By MRI: 
• Regional RV akinesia or dyskinesia or dyssynchronous RV contraction 
• and 1 of the following: 
___Ratio of RVEDV to BSA ≥100 to <110mL/m2 (male) or ≥90 to <100mL/m2 
(fem) 
___or RV EF >40% to ≤45% 
 
 II. Tissue characterization of wall 
 
Major  
• Fibrofatty replacement of myocardium on 
endomyocardial biopsy 
 
 
• Residual myocytes < 60% by morphometric analysis (or <50% if estimated), 
w/fibrosis replacement of RV free wall myocardium in ≥1 sample, w/ or w/o fatty 
replacement of tissue on endomyocardial biopsy 
 
Minor   
• Residual myocytes 60% to 75% by morphometric analysis (or 50% to 60% if est.) 
w/fibrous replacement of the RV free wall in ≥1 sample, w/ or w/o fatty 
replacement 
of tissue on endomyocardial biopsy 
 
 III. Repolarization abnormalities 
 
Major   
• TWI (V1, V2, V3) or beyond; >14 yrs; in absence of complete RBBB QRS ≥120 
ms 
 
Minor  
• TWI in right precordial leads (V2 and V3) 
(people age >12 yrs, in absence of RBBB) 
 
• TWI in V1 and V2; >14 yrs; in absence of complete RBBB or in V4, V5, or V6 
• TWI in V1 -V4; >14 yrs; in presence of complete RBBB 
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 IV. Depolarization/conduction abnormalities 
 
Major  
• Epsilon waves or localized prolongation 
(>110ms) of QRS complex in right precordial 
leads (V1 to V3) 
 
 
• Epsilon wave (reproducible low-amp signals btn end of QRS complex to onset of 
T wave) in right precordial leads (V1-V3) 
Minor  
• late potentials (SAECG) 
 
 
• LP by SAECG in ≥1 of 3 parameters in absence of QRS duration of ≥110ms on 
ECG 
___ Filtered QRS duration (fQRS) ≥114ms 
___ Duration of terminal QRS <40μV (LAS duration) ≥38ms 
___ RMS voltage of terminal 40 ms ≤20μV 
• TAD of QRS ≥55ms measured from nadir of S wave to end of QRS, including R', 
in V1, V2, or V3, in absence of complete RBBB 
 
 V. Arrhythmias 
 
Major   
• LBS NSVT or sustained VT (neg or indet QRS in II, III, and aVF and pos in 
aVL) 
 
Minor  
• LBBB sustained or NSVT (ECG, Holter, 
ETT) 
• >1000 ventricular extrasystoles per 24 hours 
(Holter) 
 
 
• NSVT or sustained VT of RV outflow configuration, LBI (pos QRS in II, III, and 
aVF and neg in aVL) or of unknown axis 
• >500 ventricular extrasystoles per 24 hours (Holter) 
 
 VI. Family History 
 
Major  
• Familial disease confirmed at necropsy or 
surgery 
 
• ARVC/D confirmed in FDR who meets TFC 
• ARVC/D confirmed pathologically at autopsy or surgery in FDR 
• Pathogenic mutation (assoc or probably assoc w/ ARVC/D) in pt under eval 
 
Minor  
• Fam hx of SD (<35yrs) due to suspected 
ARVC/D 
• Familial hx (clinical dx based on present 
criteria) 
 
 
• Hx of ARVC in FDR in whom not poss or pract to determine if FM meets TFC 
• Premature SD (<35 yrs) due to suspected ARVC/D in FDR 
• ARVC/D confirmed pathologically or by current TFC in 2ndDR 
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APPENDIX D 
P.I.D #:___________ 
Date: ____________ 
Patient Information 
 
Last name: ______________________ First: ________________ Maiden:____________ 
 
Address: ________________________________________________________________ 
 
 __________________________________________________________________ 
 
Phone #: (H) ________________ (W) _______________ (cell) ____________________ 
 
D.O.B. (DD/MM/YYYY): ______________________ 
 
Sex:  M F     Height: ______________ Weight:______________ 
 
Medical History 
 
1) When were you first diagnosed with Arrhythmogenic Right Ventricular 
Cardiomyopathy? _________________________ 
 
2) When did you receive your implantable cardioverter-defribrillator (ICD)? (DD/MM/YYYY) 
___________________________ 
 
3) When did you receive your first appropriate shock from your the ICD?  (DD/MM/YYYY)  
__________________ 
 
4) How many times has your ICD given appropriate shocks? _________________ 
Dates of shocks? (DD/MM/YYYY) 1._________________2._________________ 
3._______________4._______________5.______________6._______________ 
 
5) What activity were you doing at the time of the ICD discharge(s)? 
1._______________________________ 2._____________________________ 
 3.________________________________4._____________________________ 
5.________________________________6._____________________________ 
 
      6)   What activities were you doing the day of the ICD discharge(s)?  
1.________________________________2._____________________________ 
 3.________________________________4._____________________________ 
5.________________________________6._____________________________ 
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PHYSICAL ACTIVITY ASSESSMENT 
PLEASE ANSWER THE FOLLOWING QUESTIONS BASED ON YOUR DAILY 
PHYSICAL ACTIVITY HABITS DURING THE YEAR BEFORE YOU RECEIVED 
YOUR ICD, OR THE YEAR BEFORE YOU DEVELOPED SYMPTOMS WHICH 
PREVENTED YOU FROM EXERCISING. 
 
1. How many flights of stairs did you usually climb up each day? (1 flights = 10 steps) 
_______________________________________________________ 
 
2. How many kilometers did you regularly walk each day? _______________ 
 
3. List any sports, leisure or recreational activities that you may have participated in during 
a typical WEEK that year. Only include the amount of time that you would have been 
physically active (i.e. actual time jogging, biking, brisk walking, gardening, carpentry, 
cutting wood, curling, mowing lawn, cleaning the house, calisthenics, etc.) 
 
Sport, Recreation or other physical activity  # of times/  Average time/ 
WEEK   EPISODE 
          Hours & Minutes 
 1.___________________________________ _______ ____     ___ 
 2.___________________________________ _______ ____     ___ 
 3.___________________________________ _______ ____     ___ 
 4.___________________________________ _______ ____     ___ 
 5.___________________________________ _______ ____     ___ 
 6.___________________________________ _______ ____     ___ 
 
4. List any OTHER sports or recreational activities that you may have participated in that 
YEAR. PLEASE REMEMBER SEASONAL SPORTS OR EVENTS. 
 
Sport, Recreation or other physical activity  # of weeks/  Average time/  
        year  week 
          Hours & Minutes 
 1.___________________________________ _______ ____    ___ 
 2.___________________________________ _______ ____    ___ 
 3.___________________________________ _______ ____    ___ 
 4.___________________________________ _______ ____    ___ 
 5.___________________________________ _______ ____    ___ 
 6.___________________________________ _______ ____    ___ 
  
5. At least once a week did you engage in regular activity akin to brisk walking, jogging, 
bicycling etc. long enough to get your heart thumping or get you out of breath?   
________yes   _________no  
 If yes, how many times per week? ___________________ 
 
 
